var title_f23_27_23984="Oblique fracture middle toe";
var content_f23_27_23984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oblique fracture of the middle toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A is an AP view. Panel B is an oblique view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23984=[""].join("\n");
var outline_f23_27_23984=null;
var title_f23_27_23985="Developing dominant follicle";
var content_f23_27_23985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Developing dominant follicle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasonography of an ovary during the follicular phase of the menstrual cycle. The red arrow points to the dominant follicle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Judith Adams, DMU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23985=[""].join("\n");
var outline_f23_27_23985=null;
var title_f23_27_23986="Common blue nevus";
var content_f23_27_23986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common blue nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blue nevus in a typical location on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23986=[""].join("\n");
var outline_f23_27_23986=null;
var title_f23_27_23987="Cromolyn sodium (nasal): Drug information";
var content_f23_27_23987=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/12/197?source=see_link\">",
"    see \"Cromolyn sodium (nasal): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=see_link\">",
"    see \"Cromolyn sodium (nasal): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13319698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NasalCrom&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8011994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cromolyn Nasal Spray&reg; [OTC];",
"     </li>",
"     <li>",
"      Rhinaris-CS Anti-Allergic Nasal Mist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8105265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Mast Cell Stabilizer",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8012141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic rhinitis (treatment and prophylaxis):",
"     </b>",
"     Intranasal: Instill 1 spray in each nostril 3-4 times/day; may be increased to 6 times/day (symptomatic relief may require 2-4 weeks)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8012140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=see_link\">",
"      see \"Cromolyn sodium (nasal): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic rhinitis (treatment and prophylaxis):",
"     </b>",
"     Intranasal: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8012142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as sodium [spray]: 40 mg/mL (26 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NasalCrom&reg;: 40 mg/mL (13 mL) [contains benzalkonium chloride; 5.2 mg/inhalation]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8011996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8012194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Clear nasal passages by blowing nose prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8011997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Prevention and treatment of seasonal and perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8011992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NasalCrom&reg; may be confused with Nasacort&reg;, Nasalide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8012097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Respiratory: Increase in sneezing, burning, stinging, or irritation inside of nose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Unpleasant taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hoarseness, cough, postnasal drip",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Epistaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8012093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cromolyn or any component of the formulation; acute asthma attacks",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8012094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Prophylactic drug with no benefit for acute situations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Caution should be used when withdrawing the drug or tapering the dose as symptoms may reoccur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13763439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; however, studies in pregnant women have not shown signs of adverse effects  or increased teratogenicity with use during pregnancy (Gilbert, 2005; Mazzotta, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8012207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Cromolyn Sodium Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.2 mg/ACT (26 mL): $12.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (NasalCrom Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.2 mg/ACT (13 mL): $8.39",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cromal AQ (IN, MY);",
"     </li>",
"     <li>",
"      Cromohexal (CZ, HN, PL, TW, ZA);",
"     </li>",
"     <li>",
"      Cromorhinol (FR);",
"     </li>",
"     <li>",
"      Cronase (IL);",
"     </li>",
"     <li>",
"      Dadcrome (HK);",
"     </li>",
"     <li>",
"      Fenolip (PT);",
"     </li>",
"     <li>",
"      Ifiral (IN);",
"     </li>",
"     <li>",
"      Intal (BR);",
"     </li>",
"     <li>",
"      Lomudal (DK, FI, GR, NO, SE);",
"     </li>",
"     <li>",
"      Lomusol (AT, BE, FR, NL);",
"     </li>",
"     <li>",
"      Nazotral (CO);",
"     </li>",
"     <li>",
"      Rexacrom (NZ);",
"     </li>",
"     <li>",
"      Rilan Nasal (BR);",
"     </li>",
"     <li>",
"      Rynacrom (AU, GB, IE);",
"     </li>",
"     <li>",
"      Suallergic (TW);",
"     </li>",
"     <li>",
"      Vividrin (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8012132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Response to treatment: May occur at 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 80-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (equal amounts as unchanged drug); exhaled gases (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert C, Mazzotta P, Loebstein R, et al, \"Fetal Safety of Drugs Used in the Treatment of Allergic Rhinitis: A Critical Review,\"",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2005, 28(8):707-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/27/23987/abstract-text/16048356/pubmed\" id=\"16048356\" target=\"_blank\">",
"        16048356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazzotta P, Loebstein R, and Koren G, \"Treating Allergic Rhinitis in Pregnancy. Safety Considerations,\"",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1999, 20(4):361-75.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9080 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23987=[""].join("\n");
var outline_f23_27_23987=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319698\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8105265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012141\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012140\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012142\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795907\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795908\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012205\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012194\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011997\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011992\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012097\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012093\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012094\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299100\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012122\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763439\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012207\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961965\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012132\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9080|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/12/197?source=related_link\">",
"      Cromolyn sodium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=related_link\">",
"      Cromolyn sodium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/46/17124?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_27_23988="Actinic keratosis - dorsal hand";
var content_f23_27_23988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actinic keratosis. Scale overlies erythematous macules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23988=[""].join("\n");
var outline_f23_27_23988=null;
var title_f23_27_23989="ASCCP guidelines CIN 1 after high grade cytology";
var content_f23_27_23989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 678px\">",
"   <div class=\"ttl\">",
"    Management of CIN 1 preceded by high-grade squamous or atypical glandular cytology: American Society for Colposcopy and Cervical Pathology guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 658px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ^ Except in special populations.",
"     <br>",
"       Includes referral cytology, colposcopic findings, and all biopsies.",
"      <br>",
"       * Provided colposcopy is satisfactory and endocervical sampling is negative. If not, diagnostic excisional procedure.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: The Journal of Lower Genital Tract Diseases Vol. 11 Issue 4, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2007. No copies of the algorithms may be made without the prior consent of ASCCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23989=[""].join("\n");
var outline_f23_27_23989=null;
var title_f23_27_23990="Differential diagnosis of suspected child abuse";
var content_f23_27_23990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of suspected child abuse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23990/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23990/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23990/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23990/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23990/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23990/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23990/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/27/23990/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating the child who is suspected of being physically abused, it is important to remember that findings that appear to be abusive may result from other causes. The differential diagnosis of child abuse varies depending upon the clinical manifestations. Familiarity with the medical conditions or cultural practices that mimic child abuse can facilitate arrival at the correct diagnosis, initiation of appropriate therapy, and avoidance of the consequences of an unnecessary report of suspected child abuse.",
"   </p>",
"   <p>",
"    The differential diagnosis of the common clinical manifestations of child abuse is presented in this topic review. The clinical manifestations of child abuse and the diagnostic evaluation for suspected child abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRUISES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bruises are the most common type of injury in abused children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to intentional and unintentional bruising, the differential diagnosis of bruising includes a number of medical disorders, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bleeding disorders",
"     </li>",
"     <li>",
"      Salicylate ingestion",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and other vasculitides",
"     </li>",
"     <li>",
"      Mongolian spots",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bleeding disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding disorders include factor VIII and IX deficiencies, von Willebrand disease, immune thrombocytopenia (ITP), and thrombocytopenia caused by leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2\">",
"     2",
"    </a>",
"    ]. When bleeding is caused by bleeding disorders, the bruises usually are uniform in color. In contrast, inflicted bruises may have different colors because they are in different stages of healing. Bleeding disorders and thrombocytopenia usually can be diagnosed with clotting studies or a complete blood count, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=see_link\">",
"     \"Clinical manifestations and evaluation of thrombocytopenia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Salicylate ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate ingestion can cause bruising because of decreased platelet adhesion and increase in capillary permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2\">",
"     2",
"    </a>",
"    ]. Children with salicylate ingestion usually have other clinical signs such as vomiting, hyperventilation, and metabolic acidosis. The diagnosis is confirmed with a measurement of plasma salicylate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and other vasculitides have purpuric lesions caused by breakdown of the capillary walls (",
"    <a class=\"graphic graphic_picture graphicRef62546 \" href=\"UTD.htm?29/6/29794\">",
"     picture 1",
"    </a>",
"    ). These lesions can be mistaken for child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mongolian spots",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mongolian spots are bluish-green areas of skin discoloration often seen in African-American, Hispanic, or Asian infants up to the age of one year. They are seen most commonly on the buttocks and lower back, but may extend over the entire back (",
"    <a class=\"graphic graphic_picture graphicRef77805 \" href=\"UTD.htm?29/11/29875\">",
"     picture 2",
"    </a>",
"    ). At first glance, they may be confused easily with fresh bruising, but Mongolian spots fade over months to years rather than days. The characteristic coloring and location of Mongolian spots and the absence of swelling or tenderness also help to differentiate them from bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H16#H16\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Congenital dermal melanocytosis (Mongolian spot)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FRACTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of inflicted fractures includes accidental trauma, normal variants, pathologic fractures from metabolic bone disease or neoplasm, osteogenesis imperfecta, periosteal reaction from drugs or infection, and congenital insensitivity to pain. These conditions and their distinction from child abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11641?source=see_link\">",
"     \"Differential diagnosis of the orthopedic manifestations of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BURNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of burns in possible victims of child abuse includes intentional and unintentional burns, phytophotodermatitis, various complementary and alternative therapies, and impetigo. The differences between intentional and unintentional burns are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link&amp;anchor=H13#H13\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Burns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Phytophotodermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phytophotodermatitis is a burn-like skin lesion that occurs when sunlight interacts with photosensitizing compounds (eg, bergamot, psoralen) found in certain fruits, vegetables, or fragrance products; limes are most common, but lemons, figs, parsnips, and celery also have been implicated (",
"    <a class=\"graphic graphic_table graphicRef57164 \" href=\"UTD.htm?18/56/19339\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. The burn-like lesions are characterized by erythema and bullae, often in unusual patterns corresponding to the contact (streaks from dripping juice, handprints from adults handling the sensitizing material and then the child) or around the hands and mouth after the child handles or ingests the agent (",
"    <a class=\"graphic graphic_picture graphicRef76127 \" href=\"UTD.htm?14/27/14768\">",
"     picture 3",
"    </a>",
"    ). The eruption typically appears hours to days after exposure, which can make the lesion more difficult to relate to the contact [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Complementary and alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Garlic application to the skin of infants as a naturopathic remedy has been reported to cause bullae and partial thickness burns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Additional culture-specific complementary and alternative therapies that may cause blisters or burns to the skin are discussed below (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Cultural practices'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Impetigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impetigo is a skin infection, usually caused by staphylococci or streptococci, that can look similar to a cigarette burn (",
"    <a class=\"graphic graphic_picture graphicRef75066 \" href=\"UTD.htm?2/24/2447\">",
"     picture 4",
"    </a>",
"    ). Impetigo involves only the superficial layers of the skin; the lesions are flat, crusted, and heal cleanly. In contrast, cigarette burns penetrate more deeply (usually third-degree), have heaped-up margins, and heal with scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CONGENITAL INSENSITIVITY TO PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary sensory autonomic neuropathies are a rare group of disorders of the peripheral nerves in which the victim is unable to sense pain and often temperature, whereas all other sensation (light touch, deep touch, proprioception) remains intact [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These disorders may be inherited in an autosomal dominant or recessive fashion, or may be sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of the lack of pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temperature sensation, injuries and secondary infections are common occurrences. Injuries include bruises, burns, lacerations, fractures, and bite wounds (often self-inflicted because of the lack of pain, resulting in mutilation or amputation of the lips or fingertips). The wounds typically are undetected by caretakers because of the lack of complaint from the child. If the wounds remain open, they may become infected, leading to bacteremia, osteomyelitis, and other sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiographs may demonstrate multiple fractures of varying ages, and residual deformities from undetected and unset fractures are common occurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/10\">",
"     10",
"    </a>",
"    ]. Even fractures that are diagnosed and immobilized may heal poorly because of continued weight-bearing on the affected limb [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/9\">",
"     9",
"    </a>",
"    ]. The fracture patterns may be similar to those seen in intentional injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast to the radiographic findings in the severe forms of OI, the bones are of normal density [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of congenital insensitivity to pain can be made by taking a careful history and performing a thorough neurologic evaluation that includes pain and temperature testing. Sensory nerve conduction velocity is slowed or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/12\">",
"     12",
"    </a>",
"    ], and nerve biopsy may reveal a decrease in myelination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/8\">",
"     8",
"    </a>",
"    ] or fewer unmyelinated fibers than normal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/9\">",
"     9",
"    </a>",
"    ]. One type (Type 4, congenital insensitivity to pain and anhidrosis) involves recurrent unexplained episodes of hyperpyrexia in infancy caused by the absence of sweating [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/13\">",
"     13",
"    </a>",
"    ]. Anhidrosis may be secondary to the lack of innervation of the eccrine sweat glands [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link&amp;anchor=H13#H13\">",
"     \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN4'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CULTURAL PRACTICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cultures use various means to mark the skin in order to treat various illnesses and conditions. They include cupping, coining, spooning, moxibustion, caida de mollera, and salting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cupping",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cupping, an alcohol-soaked cotton ball is placed in a cup and ignited, the cotton ball removed, and the heated cup immediately inverted and placed on the skin. The suction force created by the cooling and contracting of the heated air is thought to \"draw out\" the ailment. The heated air and the rim of the cup burn the skin. This technique is used in Middle Eastern, Asian, Latin American, and Eastern European cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Cupping presents as circular burns, usually on the back. Central ecchymosis or petechiae result from the suction effect of the heated air as it cools and contracts (",
"    <a class=\"graphic graphic_picture graphicRef64961 \" href=\"UTD.htm?5/11/5298\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Coining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coining is used in Southeast Asian cultures to treat fever, headache, and chills [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In Vietnamese, this process is referred to as \"cao gio\" or \"scratch the wind\" since it is thought to release illness-causing \"bad winds\" from the body [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Oiled skin is rubbed firmly with the edge of a coin, producing linear red marks, usually on the back. Serious complications, including severe burns that required skin grafting when the oil on the skin caught fire, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Spooning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spooning (\"quat sha\") is similar to coining and is used in China to rid the body of the evil spirits that are thought to cause illness. In this procedure, wet skin is rubbed with a porcelain spoon, producing ecchymosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,16\">",
"     2,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Moxibustion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moxibustion is the therapeutic burning of pieces of moxa herb (mugwort or Artemisia vulgaris) or yarn on the skin. It is used in Southeast Asia, where it is considered a form of acupuncture. The lesions of moxibustion appear as a pattern of small discrete circular burns and may be confused with cigarette burns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,16,20\">",
"     2,16,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Caida de mollera",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Caida de mollera\" refers to a sunken anterior fontanel, associated with a \"bolita\" or bump on the hard palate that is believed in some Mexican-American subcultures to cause illness. Attempts to correct this condition may include any combinations of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poultices of herbs, raw egg,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soap shavings over the fontanel [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/16,19\">",
"       16,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Shaving of the head over the fontanel [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Oral suction over the fontanel by a curandero or folk healer [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,16,21\">",
"       2,16,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pressure on the hard palate [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/16,22\">",
"       16,22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immersion of the top of the head in water [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/19,23\">",
"       19,23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Slapping of the soles of the feet or shaking the infant vertically while holding him or her upside down.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last maneuver has been proposed to cause the physical findings characteristic of shaken baby syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/2,16,21,22\">",
"     2,16,21,22",
"    </a>",
"    ]. However, a detailed analysis of the cultural practice demonstrates that this may not be the case [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/16\">",
"     16",
"    </a>",
"    ]. The \"shaking\" reported by the observers is not violent, the motion is not rotational, and there have been no reports of intracranial or retinal hemorrhages associated with the practice since the first case was reported in 1972 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/19\">",
"     19",
"    </a>",
"    ], despite its ongoing use in Mexican and Mexican-American communities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=see_link\">",
"     \"Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=see_link\">",
"     \"Child abuse: Eye findings in children with abusive head trauma (AHT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Salting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salting (application of salt to the skin, or packing in salt) is an old Turkish custom that is thought to improve the health of a newborn's skin. A case of epidermolysis, severe hypernatremia, and death in a 30-day-old infant who had been intermittently salted since birth has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23990/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18684687\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familiarity with the medical conditions or cultural practices that mimic child abuse can facilitate arrival at the correct diagnosis, initiation of appropriate therapy, and avoidance of the consequences of an unnecessary report of suspected child abuse. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undiagnosed bleeding disorders, salicylate ingestion, vasculitis, and Mongolian spots comprise the most common medical disorders mistaken for inflicted bruising in children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Bruises'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lesions that appear like burns may arise from phytophotodermatitis, impetigo, or various complementary and alternative medicine therapies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Burns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary sensory autonomic neuropathies are a rare group of disorders of the peripheral nerves in which the victim is unable to sense pain and often temperature, whereas all other sensation (light touch, deep touch, proprioception) remains intact. These patients may develop multiple different types of injuries. Specific clinical findings may include slow or absent sensory nerve conduction, absent myelin fibers around sensory nerves, hyperpyrexia, and absence of sweating. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Congenital insensitivity to pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many cultures use various means to mark the skin in order to treat various illnesses and conditions. They include cupping, coining, spooning, moxibustion, caida de mollera, and salting. These practices produce skin lesions that are characteristic and may be confused with inflicted injury. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cultural practices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/1\">",
"      Naidoo S. A profile of the oro-facial injuries in child physical abuse at a children's hospital. Child Abuse Negl 2000; 24:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/2\">",
"      Stewart GM, Rosenberg NM. Conditions mistaken for child abuse: Part II. Pediatr Emerg Care 1996; 12:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/3\">",
"      Daly KC, Siegel RM. Henoch-Sch&ouml;nlein purpura in a child at risk of abuse. Arch Pediatr Adolesc Med 1998; 152:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/4\">",
"      Bergeson PS, Weiss JC. Picture of the month. Phytophotodermatitis. Arch Pediatr Adolesc Med 2000; 154:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/5\">",
"      Gruson LM, Chang MW. Berloque dermatitis mimicking child abuse. Arch Pediatr Adolesc Med 2002; 156:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/6\">",
"      Garty BZ. Garlic burns. Pediatrics 1993; 91:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/7\">",
"      Parish RA, McIntire S, Heimbach DM. Garlic burns: a naturopathic remedy gone awry. Pediatr Emerg Care 1987; 3:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/8\">",
"      Stewart GM, Rosenberg NM. Conditions mistaken for child abuse: Part I. Pediatr Emerg Care 1996; 12:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/9\">",
"      Karmani S, Shedden R, De Sousa C. Orthopaedic manifestations of congenital insensitivity to pain. J R Soc Med 2001; 94:139.",
"     </a>",
"    </li>",
"    <li>",
"     Albert MJ, Drvaric DM. Injuries resulting from pathologic forces: child abuse. In: Pediatric Fractures: A Practical Approach to Assessment and Treatment, MacEwen GD, Kasser JR, Heinrich SD.  (Eds), Williams &amp; Wilkins, Baltimore 1993. p.388.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/11\">",
"      KEMPE CH, SILVERMAN FN, STEELE BF, et al. The battered-child syndrome. JAMA 1962; 181:17.",
"     </a>",
"    </li>",
"    <li>",
"     Aicardi J. Diseases of the Nervous System in Childhood, Cambridge University, London 1998. p.719.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/13\">",
"      Edwards-Lee TA, Cornford ME, Yu KT. Congenital insensitivity to pain and anhidrosis with mitochondrial and axonal abnormalities. Pediatr Neurol 1997; 17:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/14\">",
"      Sztriha L, Lestringant GG, Hertecant J, et al. Congenital insensitivity to pain with anhidrosis. Pediatr Neurol 2001; 25:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/15\">",
"      Ravanfar P, Dinulos JG. Cultural practices affecting the skin of children. Curr Opin Pediatr 2010; 22:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/16\">",
"      Hansen KK. Folk remedies and child abuse: a review with emphasis on caida de mollera and its relationship to shaken baby syndrome. Child Abuse Negl 1998; 22:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/17\">",
"      Ponder A, Lehman LB. 'Coining' and 'coning': an unusual complication of unconventional medicine. Neurology 1994; 44:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/18\">",
"      Crutchfield CE 3rd, Bisig TJ. Images in clinical medicine. Coining. N Engl J Med 1995; 332:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/19\">",
"      Guarnaschelli J, Lee J, Pitts FW. \"Fallen fontanelle\" (caida de Mollera). A variant of the battered child syndrome. JAMA 1972; 222:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/20\">",
"      Frechette A, Rimsza ME. Stun gun injury: a new presentation of the battered child syndrome. Pediatrics 1992; 89:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/21\">",
"      Caffey J. The whiplash shaken infant syndrome: manual shaking by the extremities with whiplash-induced intracranial and intraocular bleedings, linked with residual permanent brain damage and mental retardation. Pediatrics 1974; 54:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/22\">",
"      Lindstrom CJ. The boiled fontanelle in Caida de Mollera. JAMA 1973; 225:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/23\">",
"      Schwengel D, Ludwig S. Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care 1985; 1:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23990/abstract/24\">",
"      Yercen N, Caglayan S, Y&uuml;cel N, et al. Fatal hypernatremia in an infant due to salting of the skin. Am J Dis Child 1993; 147:716.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6601 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23990=[""].join("\n");
var outline_f23_27_23990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18684687\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRUISES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Salicylate ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mongolian spots",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FRACTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BURNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Phytophotodermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Complementary and alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CONGENITAL INSENSITIVITY TO PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CULTURAL PRACTICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cupping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Coining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Spooning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Moxibustion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Caida de mollera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Salting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18684687\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6601|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/6/29794\" title=\"picture 1\">",
"      Petechiae in Henoch Schonlein purpura IgA vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/11/29875\" title=\"picture 2\">",
"      Mongolian spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/27/14768\" title=\"picture 3\">",
"      Phytophotodermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/24/2447\" title=\"picture 4\">",
"      Impetigo vesiculopustules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/11/5298\" title=\"picture 5\">",
"      Cupping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/56/19339\" title=\"table 1\">",
"      Phytophotodermatitis agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=related_link\">",
"      Approach to evaluating childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32985?source=related_link\">",
"      Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20602?source=related_link\">",
"      Child abuse: Eye findings in children with abusive head trauma (AHT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24295?source=related_link\">",
"      Clinical manifestations and evaluation of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11641?source=related_link\">",
"      Differential diagnosis of the orthopedic manifestations of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_27_23991="Microbiology, epidemiology, and pathogenesis of nocardiosis";
var content_f23_27_23991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, epidemiology, and pathogenesis of nocardiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23991/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23991/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23991/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23991/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23991/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/27/23991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardiosis is an uncommon gram-positive bacterial infection caused by aerobic actinomycetes in the genus Nocardia. Nocardia spp have the ability to cause localized or systemic suppurative disease in humans and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Nocardiosis is typically regarded as an opportunistic infection, but approximately one-third of infected patients are immunocompetent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Immunocompromise'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two characteristics of nocardiosis are its ability to disseminate to virtually any organ, particularly the central nervous system, and its tendency to relapse or progress despite appropriate therapy.",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, and pathogenesis of nocardiosis will be reviewed here. The clinical manifestations, complications, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinomycetes are a group of aerobic and anaerobic bacteria in the order Actinomycetales. These organisms are phylogenetically diverse but morphologically similar, exhibiting characteristic filamentous branching with fragmentation into bacillary or coccoid forms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/6\">",
"     6",
"    </a>",
"    ]. Aerobic actinomyces that cause human and veterinary disease include Nocardia, Gordona, Tsukamurella, Streptomyces, Rhodococcus, Streptomycetes, Mycobacteria, and Corynebacteria. Anaerobic genera of medical importance include Actinomyces, Arachnia, Rothia, and Bifidobacterium.",
"   </p>",
"   <p>",
"    Nocardia typically appear as delicate filamentous gram-positive branching rods (",
"    <a class=\"graphic graphic_picture graphicRef80426 \" href=\"UTD.htm?15/61/16336\">",
"     picture 1",
"    </a>",
"    ) that appear similar to Actinomyces species. Nocardia can usually be differentiated from Actinomyces by acid-fast staining, as Nocardia typically exhibit varying degrees of acid fastness due to the mycolic acid content of the cell wall (",
"    <a class=\"graphic graphic_picture graphicRef66553 \" href=\"UTD.htm?14/36/14913\">",
"     picture 2",
"    </a>",
"    ). Another useful clue is that Nocardia grow under aerobic conditions, whereas Actinomyces grow under anaerobic conditions.",
"   </p>",
"   <p>",
"    In the laboratory, Nocardia can display both aerial branching and substrate branching into the media or along its surface. These organisms were once considered fungi because of their hyphal-like appearance, but molecular analysis of their cell wall has confirmed their classification as bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TAXONOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Nocardia includes more than 80 species, at least 33 of which cause disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/1,4,7\">",
"     1,4,7",
"    </a>",
"    ]. Nocardia species were originally classified based upon biochemical properties. However, classification has become more complex with the use of antibiotic susceptibility profiles, which have revealed marked heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/4,6,8\">",
"     4,6,8",
"    </a>",
"    ], and molecular techniques, such as analysis of the 16S rRNA gene, restriction fragment length polymorphisms, and multilocus sequence analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/9-13\">",
"     9-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    N. asteroides, formerly considered the most common species associated with human disease, has been redefined as a complex that includes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/4,6,14,15\">",
"     4,6,14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      N. asteroides sensu stricto",
"     </li>",
"     <li>",
"      N. farcinica",
"     </li>",
"     <li>",
"      N. nova",
"     </li>",
"     <li>",
"      N. transvalensis complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    N. farcinica appears to be more virulent than the other members of the N. asteroides complex, since infection with this species is more likely to result in disseminated disease and tends to be more resistant to antimicrobials, especially third-generation cephalosporins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ]. N. nova has a different susceptibility pattern, showing consistent susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/4,6,15\">",
"     4,6,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular studies indicate that N. brasiliensis, N. otitidiscaviarum, and N. transvalensis, once thought to be fairly homogeneous genera, also exhibit diverse characteristics, and it is anticipated that new species will continue to emerge [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686793549\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia species are not",
"    <strong>",
"    </strong>",
"    members of normal human flora. Nocardia species are found worldwide in soil, decaying vegetable matter, and aquatic environments, and can become airborne, particularly on dust particles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/21\">",
"     21",
"    </a>",
"    ]. Inhalation of the organism is considered to be the most common mode of entry, which is supported by the observation that the majority of infections involve the lung.",
"   </p>",
"   <p>",
"    A number of other modes of entry may be important in selected cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of contaminated food may produce disease via the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cutaneous disease usually occurs by direct inoculation of the organism as a result of trauma (including puncture by a thorn or splinter or an animal scratch or bite), surgery, a vascular catheter, or an insect bite [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3,5\">",
"       3,5",
"      </a>",
"      ]. An outbreak of N. cyriacigeorgica soft tissue infection involving eight individuals was linked to the use of unlicensed cosmetic injections [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/22\">",
"       22",
"      </a>",
"      ]. Cutaneous disease may also occur secondary to hematogenous dissemination. In such cases, lesions are typically multiple and widespread.",
"     </li>",
"     <li>",
"      Reports of case clusters support nosocomial transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. As an example, a cluster of nosocomial cases of postoperative sternal wound infection with N. farcinica was caused by an isolate that was identical to one cultured from the hands and home of a healthy healthcare worker [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the early 1970s, the incidence of nocardiosis in the United States was estimated to be approximately 500 to 1000 new cases per year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/26\">",
"     26",
"    </a>",
"    ]. This probably represented an underestimate since nocardiosis is not a reportable disease and infection is difficult to diagnose. The current incidence is likely to be much higher, as the United States population has increased substantially since then and the proportion of individuals at risk for nocardiosis has greatly increased (eg, transplant recipients and HIV-infected patients). Some authors now regard nocardiosis to be an emerging and increasing infectious disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686793576\">",
"    <span class=\"h2\">",
"     Species prevalence and distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty-three Nocardia species have been shown to cause disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/1,4,6\">",
"     1,4,6",
"    </a>",
"    ], with infection by members of the N. asteroides complex (N. asteroides sensu stricto, N. farcinica, and N. nova) being the most common worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/6\">",
"     6",
"    </a>",
"    ]. There are likely to be differences in the distribution of Nocardia spp worldwide, but this has not been well characterized due to changes in taxonomy, difficulty in routine identification of Nocardia strains at the species level, and, perhaps, referral and reporting biases.",
"   </p>",
"   <p>",
"    Among 765 isolates submitted to the United States Centers for Disease Control and Prevention between 1995 and 2004, the following species were identified most commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      N. nova complex (28 percent)",
"     </li>",
"     <li>",
"      N. brasiliensis (14 percent)",
"     </li>",
"     <li>",
"      N. farcinica (14 percent)",
"     </li>",
"     <li>",
"      N. cyriacigeorgica (formerly part of the N. asteroides complex, 13 percent)",
"     </li>",
"     <li>",
"      N. brevicatena (7 percent)",
"     </li>",
"     <li>",
"      N. abscessus (formerly part of the N. asteroides complex, 6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A somewhat different distribution of Nocardia spp was noted in a review of 303 nocardiosis cases in Japan from 1992 until 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      N. farcinica (27 percent)",
"     </li>",
"     <li>",
"      N. asteroides sensu stricto (24 percent)",
"     </li>",
"     <li>",
"      N. brasiliensis (22 percent)",
"     </li>",
"     <li>",
"      N. nova (11 percent)",
"     </li>",
"     <li>",
"      N. cyriacigeorgica (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    N. farcinica was also the most common species in a study from Belgium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/30\">",
"     30",
"    </a>",
"    ], whereas N. brasiliensis was the most common species in a study from Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For unclear reasons, males have predominated in most cases series of nocardial infection. Although it has been postulated that this male predominance may be related to occupation, there is in vitro evidence that estrogen might be protective. For example, in a murine model of N. brasiliensis-induced actinomycetoma, estradiol limited mycetoma lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686793876\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia spp possess multiple mechanisms to overcome the immune response of the host. The ability to combat host resistance to infection appears to vary with the strain and growth phase of the bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/33\">",
"     33",
"    </a>",
"    ]. Bacteria that are in log-phase exhibit filamentous growth and are resistant to phagocytosis. When phagocytosis does occur, inhibition of phagosome-lysosome fusion has been observed with some nocardial strains, thereby avoiding hydrolysis by the host cell. The production of a bacterial cell surface-associated superoxide dismutase and possibly increased production of catalase may be involved in resistance to human neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    L-forms are cell wall-deficient variants of some bacterial species, including Nocardia. L-forms have been recovered from cerebrospinal fluid (CSF) in human nocardiosis and cause disease in animal models. Lifelong persistence of L-forms has been demonstrated in murine models and it has been postulated that L-forms may be related to the tendency of nocardiosis to relapse and to recur years after successful initial antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Host defenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interplay between host defenses and nocardial infections has been studied extensively both in vivo and in vitro. Although not all mechanisms are fully understood, it is clear that cell-mediated immunity is crucial in containing Nocardia spp infection.",
"   </p>",
"   <p>",
"    The initial host response to nocardiosis involves neutrophils and local macrophages, which inhibit but do not kill the bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This inhibition helps to limit the spread of infection until a specific cell-mediated response can occur. A population of immune primed T cells enhances phagocytosis, stimulates cellular response, and may be capable of direct cytotoxicity to the bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/5,37\">",
"     5,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma delta T lymphocytes may play a crucial role in the host defenses against Nocardia spp. In a murine model, gamma delta T cell-deficient mice died within 14 days after inoculation with N. asteroides at a dose that was not lethal to control mice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/38\">",
"     38",
"    </a>",
"    ]. Lung tissue from these mice showed severe damage and growth of the organism compared to a neutrophil response and clearance of the bacteria in the control animals.",
"   </p>",
"   <p>",
"    The role of humoral immunity in nocardiosis is unknown. Murine models indicate that humoral immunity is not as critical as cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], but antibody has been demonstrated to enhance phagocytosis and the microbicidal activity of activated macrophages in a rabbit model [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/41\">",
"     41",
"    </a>",
"    ]. There is no evidence that B cells directly influence host defenses in nocardial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611540365\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunocompromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with nocardial infection are immunocompromised, most often with cell-mediated abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3,4,43\">",
"     3,4,43",
"    </a>",
"    ]. In a review of 1050 cases, for example, 64 percent were immunocompromised [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/5\">",
"     5",
"    </a>",
"    ]. The most common causes are glucocorticoid therapy, malignancy, organ and hematopoietic stem cell transplantation, and HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually every illness that requires prolonged glucocorticoid therapy has been associated with nocardiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3,44-47\">",
"     3,44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H6573898#H6573898\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Infection and immune response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solid tumors and hematologic malignancies accounted for 17 percent of cases of nocardiosis in the series of 1050 cases cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/5\">",
"     5",
"    </a>",
"    ]. In another series, hematologic malignancies were present in 64 percent of cases; almost one-half had undergone hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/44\">",
"     44",
"    </a>",
"    ]. Risk factors in such patients include recent chemotherapy, glucocorticoid administration, and antirejection drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Organ transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of nocardiosis is highest in the first year following organ transplantation, presumably due to greater immunosuppression to prevent rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3\">",
"     3",
"    </a>",
"    ]. Studies in transplant recipients treated with steroid-sparing regimens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , have found significantly reduced rates of nocardial infections: 2.6 to 0.7 percent in renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/45\">",
"     45",
"    </a>",
"    ] and 13 to &le;4 percent in later series in heart transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3,46\">",
"     3,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of and risk factors for Nocardia infection in organ transplant recipients was evaluated in a matched case-control study of 5126 organ transplant recipients, 35 of whom (0.6 percent) developed Nocardia infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/47\">",
"     47",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of Nocardia infection was highest in lung and heart transplant recipients (3.5 and 2.5 percent) and lowest in liver and kidney transplant recipients (0.1 and 0.2 percent). Most infected patients (69 percent) were being treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      prophylaxis.",
"     </li>",
"     <li>",
"      N. nova and N. farcinica accounted for 77 percent of the infections. Most patients had only pulmonary infection, but 20 percent had disseminated disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"       \"Clinical manifestations and diagnosis of nocardiosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When the patients were matched to 70 uninfected controls, independent risk factors for Nocardia infection were high-dose glucocorticoids (odds ratio 27), cytomegalovirus disease in the preceding six months (odds ratio 6.9), and high median serum calcineurin inhibitor concentrations in the preceding 30 days (odds ratio 5.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardiosis is uncommon in HIV-infected patients, occurring in 0.2 to 2 percent of patients. Most HIV-infected patients with nocardiosis are severely immunocompromised (median CD4 count of 35",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) prophylaxis for Nocardia infection to date has not shown a benefit in patients with AIDS. Reasons for this are multifactorial and may include the low frequency of disease, the increasing use of antiretroviral therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    misdiagnosis with other pulmonary infections such as tuberculosis or bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3,48,49\">",
"     3,48,49",
"    </a>",
"    ]. However, support for TMP-SMX prophylaxis was noted in a study that documented that most cases of nocardiosis occurred in AIDS patients who had not been receiving sulfonamide prophylaxis for other infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/49\">",
"     49",
"    </a>",
"    ]. Since the use of TMP-SMX prophylaxis to prevent Pneumocystis jirovecii pneumonia is routine for AIDS patients with CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    most high-risk AIDS patients receive concurrent prophylaxis for nocardiosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=see_link\">",
"     \"Bacterial pulmonary infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that have been associated with nocardiosis include diabetes mellitus, alcoholism, chronic granulomatous disease, alveolar proteinosis, tumor necrosis factor-alpha inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) therapy, chronic obstructive pulmonary disease, and tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23991/abstract/3-5,43,50\">",
"     3-5,43,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocardiosis is caused by aerobic actinomycetes in the genus Nocardia, an unusual gram-positive bacteria. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocardia typically appear as delicate filamentous gram-positive branching rods that appear similar to Actinomyces species. Nocardia spp can be differentiated from Actinomyces by acid-fast staining and their ability to grow under aerobic conditions, neither of which is a characteristic of Actinomyces. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Taxonomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genus Nocardia includes more than 80 species, at least 33 of which cause disease in humans. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Taxonomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocardia species are found worldwide in soil, decaying vegetable matter, and aquatic environments. Modes of entry include inhalation, ingestion, and direct inoculation through the skin. Inhalation is the most common route of entry. (See",
"      <a class=\"local\" href=\"#H686793549\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common Nocardia species to cause disease in the United States are members of the N. asteroides complex (N. asteroides sensu stricto, N. farcinica, and N. nova). The species prevalence has varied in studies from different geographic regions. (See",
"      <a class=\"local\" href=\"#H686793576\">",
"       'Species prevalence and distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nocardia spp possess multiple mechanisms to overcome the immune response of the host. (See",
"      <a class=\"local\" href=\"#H686793876\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cell-mediated immunity is crucial in containing Nocardia spp infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Host defenses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with nocardial infection are immunocompromised, most often with cell-mediated abnormalities. The most common causes are glucocorticoid therapy, malignancy, organ and hematopoietic stem cell transplantation, and HIV infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Immunocompromise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/1\">",
"      Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/2\">",
"      Lerner PI. Nocardiosis. Clin Infect Dis 1996; 22:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/3\">",
"      Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore) 2004; 83:300.",
"     </a>",
"    </li>",
"    <li>",
"     Sorrell TC, Mitchell DH, Iredell JR, Chen SC-A. Nocardia Species. In: Principles and Practice of Infectious Diseases, 7, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. p.3199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/5\">",
"      Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     Conville PS, Witebsky FG. Nocardia, Rhodococcus, Gordonia, Actinomadura, Streptomyces, and other Aerobic Actinomycetes. In: Manual of Clinical Microbiology, 9, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington, DC 2007. p.515.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/7\">",
"      Roth A, Andrees S, Kroppenstedt RM, et al. Phylogeny of the genus Nocardia based on reassessed 16S rRNA gene sequences reveals underspeciation and division of strains classified as Nocardia asteroides into three established species and two unnamed taxons. J Clin Microbiol 2003; 41:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/8\">",
"      Wallace RJ Jr, Steele LC, Sumter G, Smith JM. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother 1988; 32:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/9\">",
"      Steingrube VA, Brown BA, Gibson JL, et al. DNA amplification and restriction endonuclease analysis for differentiation of 12 species and taxa of Nocardia, including recognition of four new taxa within the Nocardia asteroides complex. J Clin Microbiol 1995; 33:3096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/10\">",
"      Conville PS, Fischer SH, Cartwright CP, Witebsky FG. Identification of nocardia species by restriction endonuclease analysis of an amplified portion of the 16S rRNA gene. J Clin Microbiol 2000; 38:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/11\">",
"      Laurent FJ, Provost F, Boiron P. Rapid identification of clinically relevant Nocardia species to genus level by 16S rRNA gene PCR. J Clin Microbiol 1999; 37:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/12\">",
"      Wilson RW, Steingrube VA, Brown BA, Wallace RJ Jr. Clinical application of PCR-restriction enzyme pattern analysis for rapid identification of aerobic actinomycete isolates. J Clin Microbiol 1998; 36:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/13\">",
"      McTaggart LR, Richardson SE, Witkowska M, Zhang SX. Phylogeny and identification of Nocardia species on the basis of multilocus sequence analysis. J Clin Microbiol 2010; 48:4525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/14\">",
"      Wallace RJ Jr, Tsukamura M, Brown BA, et al. Cefotaxime-resistant Nocardia asteroides strains are isolates of the controversial species Nocardia farcinica. J Clin Microbiol 1990; 28:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/15\">",
"      Wallace RJ Jr, Brown BA, Tsukamura M, et al. Clinical and laboratory features of Nocardia nova. J Clin Microbiol 1991; 29:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/16\">",
"      Cercenado E, Mar&iacute;n M, S&aacute;nchez-Mart&iacute;nez M, et al. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob Agents Chemother 2007; 51:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/17\">",
"      Schaal KP, Lee HJ. Actinomycete infections in humans--a review. Gene 1992; 115:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/18\">",
"      Wallace RJ Jr, Brown BA, Blacklock Z, et al. New Nocardia taxon among isolates of Nocardia brasiliensis associated with invasive disease. J Clin Microbiol 1995; 33:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/19\">",
"      Wilson RW, Steingrube VA, Brown BA, et al. Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 1997; 35:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/20\">",
"      Conville PS, Brown JM, Steigerwalt AG, et al. Nocardia wallacei sp. nov. and Nocardia blacklockiae sp. nov., human pathogens and members of the \"Nocardia transvalensis Complex\". J Clin Microbiol 2008; 46:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/21\">",
"      Goodfellow M, Williams ST. Ecology of actinomycetes. Annu Rev Microbiol 1983; 37:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/22\">",
"      Apostolou A, Bolcen SJ, Dave V, et al. Nocardia cyriacigeorgica infections attributable to unlicensed cosmetic procedures--an emerging public health problem? Clin Infect Dis 2012; 55:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/23\">",
"      Bl&uuml;mel J, Bl&uuml;mel E, Yassin AF, et al. Typing of Nocardia farcinica by pulsed-field gel electrophoresis reveals an endemic strain as source of hospital infections. J Clin Microbiol 1998; 36:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/24\">",
"      Exmelin L, Malbruny B, Vergnaud M, et al. Molecular study of nosocomial nocardiosis outbreak involving heart transplant recipients. J Clin Microbiol 1996; 34:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/25\">",
"      Wenger PN, Brown JM, McNeil MM, Jarvis WR. Nocardia farcinica sternotomy site infections in patients following open heart surgery. J Infect Dis 1998; 178:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/26\">",
"      Beaman BL, Burnside J, Edwards B, Causey W. Nocardial infections in the United States, 1972-1974. J Infect Dis 1976; 134:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/27\">",
"      Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010; 38:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/28\">",
"      Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis 2010; 51:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/29\">",
"      Kageyama A, Yazawa K, Ishikawa J, et al. Nocardial infections in Japan from 1992 to 2001, including the first report of infection by Nocardia transvalensis. Eur J Epidemiol 2004; 19:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/30\">",
"      Wauters G, Avesani V, Charlier J, et al. Distribution of nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol 2005; 43:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/31\">",
"      Lai CC, Liu WL, Ko WC, et al. Antimicrobial-resistant nocardia isolates, Taiwan, 1998-2009. Clin Infect Dis 2011; 52:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/32\">",
"      Hernandez-Hernandez F, Lopez-Martinez R, Mendez-Tovar LJ, Manzano-Gayosso P. Nocardia brasiliensis: in vitro and in vivo growth response to steroid sex hormones. Mycopathologia 1995; 132:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/33\">",
"      Beaman BL, Maslan S. Virulence of Nocardia asteroides during its growth cycle. Infect Immun 1978; 20:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/34\">",
"      Beaman BL, Black CM, Doughty F, Beaman L. Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun 1985; 47:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/35\">",
"      Filice GA, Beaman BL, Krick JA, Remington JS. Effects of human neutrophils and monocytes on Nocardia asteroides: failure of killing despite occurrence of the oxidative metabolic burst. J Infect Dis 1980; 142:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/36\">",
"      Filice GA. Inhibition of Nocardia asteroides by neutrophils. J Infect Dis 1985; 151:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/37\">",
"      Deem RL, Doughty FA, Beaman BL. Immunologically specific direct T lymphocyte-mediated killing of Nocardia asteroides. J Immunol 1983; 130:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/38\">",
"      King DP, Hyde DM, Jackson KA, et al. Cutting edge: protective response to pulmonary injury requires gamma delta T lymphocytes. J Immunol 1999; 162:5033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/39\">",
"      Beaman BL, Gershwin ME, Ahmed A, et al. Response of CBA/N x DBA2/F1 mice to Nocardia asteroides. Infect Immun 1982; 35:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/40\">",
"      Beaman BL. Nocardia as a pathogen of the brain: mechanisms of interactions in the murine brain--a review. Gene 1992; 115:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/41\">",
"      Davis-Scibienski C, Beaman BL. Interaction of alveolar macrophages with Nocardia asteroides: immunological enhancement of phagocytosis, phagosome-lysosome fusion, and microbicidal activity. Infect Immun 1980; 30:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/42\">",
"      Rico G, Ochoa R, Oliva A, et al. Enhanced resistance to Nocardia brasiliensis infection in mice depleted of antigen-specific B cells. J Immunol 1982; 129:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/43\">",
"      Palmer DL, Harvey RL, Wheeler JK. Diagnostic and therapeutic considerations in Nocardia asteroides infection. Medicine (Baltimore) 1974; 53:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/44\">",
"      Torres HA, Reddy BT, Raad II, et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002; 81:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/45\">",
"      Arduino RC, Johnson PC, Miranda AG. Nocardiosis in renal transplant recipients undergoing immunosuppression with cyclosporine. Clin Infect Dis 1993; 16:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/46\">",
"      Hofflin JM, Potasman I, Baldwin JC, et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/47\">",
"      Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/48\">",
"      Pintado V, G&oacute;mez-Mampaso E, Cobo J, et al. Nocardial infection in patients infected with the human immunodeficiency virus. Clin Microbiol Infect 2003; 9:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/49\">",
"      Javaly K, Horowitz HW, Wormser GP. Nocardiosis in patients with human immunodeficiency virus infection. Report of 2 cases and review of the literature. Medicine (Baltimore) 1992; 71:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23991/abstract/50\">",
"      Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5514 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23991=[""].join("\n");
var outline_f23_27_23991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TAXONOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H686793549\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686793576\">",
"      Species prevalence and distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H686793876\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Host defenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H611540365\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunocompromise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5514|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/61/16336\" title=\"picture 1\">",
"      Nocardia on Gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/36/14913\" title=\"picture 2\">",
"      Acid fast staining of Nocardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=related_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_27_23992="The difficult patient encounter";
var content_f23_27_23992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The difficult patient encounter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Auguste H Fortin, VI, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Francesca C Dwamena, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Robert C Smith, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23992/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/27/23992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from physician surveys suggest that nearly one out of six outpatient visits are considered difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1\">",
"     1",
"    </a>",
"    ]. Physicians who view a high number of their patients as difficult are more likely to be \"burned out\" and less likely to report work satisfaction than physicians who perceive having relatively fewer difficult patients.",
"   </p>",
"   <p>",
"    The last 20 years have seen an increase in study of the &ldquo;difficult patient&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1-19\">",
"     1-19",
"    </a>",
"    ]. The literature warns against considering the patient as the only cause of the problem [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1,13,14,16\">",
"     1,13,14,16",
"    </a>",
"    ]. It suggests, rather, that the clinician and the clinician-patient relationship constitute the proper focus for understanding and managing difficult patient encounters [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1-3,6-8,10-13,20-22\">",
"     1-3,6-8,10-13,20-22",
"    </a>",
"    ]. The relationship and communication between clinician-patient are key factors in understanding and caring for patients who are perceived to be &ldquo;difficult&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/14\">",
"     14",
"    </a>",
"    ]. Additionally, clinicians need to develop better understanding of their internalization of difficult patient encounters. The inscription on the temple of Apollo at Delphi provided clues to the problem of the difficult clinician-patient relationship centuries ago: \"Know yourself.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS CONTRIBUTING TO DIFFICULT PATIENT ENCOUNTERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;difficult patient&rdquo; can be defined as one who impedes the clinician's ability to establish a therapeutic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/17,23\">",
"     17,23",
"    </a>",
"    ]. Another definition is: \"a person who does not assume the patient role expected by the healthcare professional, who may have beliefs and values or other personal characteristics that differ from those of the caregiver, and who causes the caregiver to experience self-doubt\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/24\">",
"     24",
"    </a>",
"    ]. This definition highlights the literature's focus on patients' behaviors that deviate from expected patient roles, patient personal characteristics that conflict with providers' beliefs and values, and patient behaviors that are perceived to challenge providers' competence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    control.",
"   </p>",
"   <p>",
"    A number of studies have investigated the types of clinician-patient interactions that result in clinicians labeling patients as difficult.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study physicians identified 92 patients they perceived as difficult, by each clinician's own criteria. These were compared to 166 randomly selected controls [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/10\">",
"       10",
"      </a>",
"      ]. Compared to controls, the &ldquo;difficult patients&rdquo; were older [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/15\">",
"       15",
"      </a>",
"      ], more often separated or divorced, more likely to be women, had more acute and chronic problems, took more medications, underwent more x-rays and tests, were referred more often, and had more visits (6.8 versus 3.7 visits per year). Adjusting for age and sex, significant differences remained between the two groups for chronic problems, tests, medications, and visits.",
"     </li>",
"     <li>",
"      A second study used the validated Difficult Doctor-Patient Relationship Questionnaire to rate 627 patients in four primary care clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. Physicians rated 15 percent of their patients as difficult, ranging from 12 to 20 percent at different clinics. Compared to nondifficult patients, patients perceived as difficult were more likely to have a mental disorder, especially multisomatoform disorder, panic disorder, dysthymia, generalized anxiety, major depression, and alcohol abuse or dependence. These patients also had more symptoms, greater functional impairment, higher health care utilization, and lower satisfaction with their care. There were no distinguishing demographic or physical symptom characteristics.",
"      <br/>",
"      <br/>",
"      Physicians in this study often disliked &ldquo;difficult patients.&rdquo; They were unenthusiastic about providing care, saw these patients as frustrating and time-consuming, felt manipulated by them, and did not look forward to return visits. In one-half of encounters with &ldquo;difficult patients,&rdquo; physicians harbored hopes that the patient would not return. Accounting for 23 percent of variance in difficulty scores, &ldquo;difficult patient&rdquo; status was strongly associated with the total number of mental disorders, somatoform and physical symptoms, multisomatoform disorder, and alcohol abuse. The authors propose that multiple physical symptoms, especially somatization, generate distress and frustration in physicians because of uncertainty about diagnosis and treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link\">",
"       \"Somatization: Treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=see_link\">",
"       \"Primary care management of medically unexplained symptoms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A review from 1975 found that doctors and nurses described the \"good patient\" in the following terms: trusting, cooperative, noncomplaining, and nondemanding [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients who interrupted a caregiver's established routines and made extra work were considered difficult or problem patients. If &ldquo;difficult patients&rdquo; were perceived by staff as seriously ill, their complaining, emotionality, and need for attention were viewed as problematic but forgivable because the situation was beyond their control; these patients received the attention they wanted, especially if they expressed gratitude for it. Seriously-ill patients who were cheerful, cooperative, uncomplaining, and objective about their illness were viewed as \"great\" patients. Patients who were perceived as not being seriously ill but were complaining, emotional, and uncooperative were condemned by clinicians and often discharged early, tranquilized, or referred to psychiatry.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have aimed to define the patient characteristics and circumstances that produce negative reactions in physicians and lead to the &ldquo;difficult patient&rdquo; label (",
"    <a class=\"graphic graphic_table graphicRef66724 \" href=\"UTD.htm?31/50/32555\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/3,8,11,12,15,17,20,26-29\">",
"     3,8,11,12,15,17,20,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Patients' expressions of emotions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often find emotional expression by patients very troublesome, especially anger, sadness (crying), anxiety, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. Students and clinicians are often not taught how to deal with patients' emotions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/30\">",
"     30",
"    </a>",
"    ]. This is especially unfortunate because addressing patients at the emotional level is the most important determinant of a therapeutic clinician-patient relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Patients' personality features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with personality disorders (personality characteristics in the pathological extreme) almost always cause problems for clinicians. Examples of personality disorders include borderline [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/31\">",
"     31",
"    </a>",
"    ], obsessive-compulsive, dependent, self-defeating, histrionic, narcissistic, paranoid, and schizoid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even where the patient's personality structure is normal, physicians can have problems with patients' personality features: an interaction between a Type A (obsessive-compulsive) clinician and a Type A patient who tries to take control of the interaction is likely to be perceived as difficult by the doctor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/32\">",
"     32",
"    </a>",
"    ]. Others have noted that loss of control is stressful to clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/18\">",
"     18",
"    </a>",
"    ]. Clinicians might also perceive passive (dependent) patients with progressive dependence as difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Patients' personal characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Personal characteristics of the patient that differ from those of the clinician are often factors in perceiving a patient as \"difficult.\" Such characteristics may include: foreign language and other communication barriers (deaf, blind); malodorous; having a communicable disease; race or ethnicity difference; impecunious;",
"    <span class=\"nowrap\">",
"     higher/lower",
"    </span>",
"    social status; different sexual orientation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Patients' specific clinical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinical problems, especially mental health issues, cause clinicians to perceive patients as difficult. Examples include somatization (including chronic pain),",
"    <span class=\"nowrap\">",
"     drug/alcohol",
"    </span>",
"    abuse, psychiatric problems, sexual problems, organic mental syndromes, cancer, suicidality, worsening or undiagnosable medical problem, noncompliance,",
"    <span class=\"nowrap\">",
"     death/dying,",
"    </span>",
"    discussing end-of-life care and advance directives, and adverse health behaviors. &ldquo;Difficult patients&rdquo; tend to have more symptoms, vaguer symptoms, poorer self-rated health, and more symptom amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. As prescription substance misuse has become more prevalent, classification of over one-third of patients perceived as difficult in one study stemmed from their requests for unnecessary medications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Patients' direct demands/stresses on the clinician",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who place direct demands or stresses on their clinicians cause the greatest discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/26\">",
"     26",
"    </a>",
"    ]. With few exceptions, threat of dismissal by the patient identifies a &ldquo;difficult patient,&rdquo; as does the patient who disagrees strongly with an explanation or recommendation, or the patient who complains about care or the health system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1\">",
"     1",
"    </a>",
"    ]. Other circumstances leading to the &ldquo;difficult patient&rdquo; label include the patient who requires more time than is available, the seductive patient, the aggressive or threatening patient, and someone with many legal or insurance papers to fill out. The patient with unnecessary lab, referral, medication, and disability requests, or who wants social interactions or advice about nonmedical issues, also is usually seen as difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinician characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinician characteristics increase the likelihood of viewing patients as difficult (",
"    <a class=\"graphic graphic_table graphicRef67125 \" href=\"UTD.htm?0/61/987\">",
"     table 2",
"    </a>",
"    ). Clinicians who are overworked may perceive more patients as difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1,2,13\">",
"     1,2,13",
"    </a>",
"    ]. Patients are perceived as difficult when their clinicians dislike them or their circumstances (ie, there is a relationship problem) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/11\">",
"     11",
"    </a>",
"    ]. It is the clinician's responsibility more than the patient's to address and resolve the relationship problem. We have far more access to and control over our own reactions than we have over the patient's.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5606995\">",
"    <span class=\"h3\">",
"     Clinicians' psychosocial training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients' psychosocial problems and issues often lead clinicians to label them as difficult. Physicians and students receive little training in psychosocial medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/33\">",
"     33",
"    </a>",
"    ]. Rather, their predominantly biomedical training focuses upon organic disease, where a so-called good patient presents, according to one author, with \"objective signs and symptoms of a treatable disease process, makes no emotional demands on the clinician, cooperates in the treatment process (ie, obeys orders), and upon getting well displays gratitude for the help received\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/34\">",
"     34",
"    </a>",
"    ]. This biomedical focus during training may lead to poor psychosocial attitudes, causing physicians to view more of their patients as difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Streptococcal pharyngitis, angina pectoris, and appendicitis are examples of illnesses where the biomedical model can be effective. However, most patients do not fit the biomedical paradigm. Over one-half of outpatients have no organic disease at all [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/35-37\">",
"     35-37",
"    </a>",
"    ], and only 16 percent of new complaints have an organic disease basis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, many patients who have organic diseases also have complicating psychosocial issues (eg, noncompliance, depression, insurance issues) that make them difficult. Thus, the typical &ldquo;good patient&rdquo; is the uncommon patient with a treatable organic disease and no psychosocial problems. The typical &ldquo;difficult patient&rdquo; may or may not have an organic disease but does have significant psychosocial problems.",
"   </p>",
"   <p>",
"    Psychosocial medicine training can effectively address the &ldquo;difficult patient&rdquo; problem [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. &ldquo;Difficult patients&rdquo; with medically unexplained symptoms can be effectively managed by primary care clinicians. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8249?source=see_link\">",
"     \"Patient-centered interviewing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=see_link\">",
"     \"Primary care management of medically unexplained symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5607123\">",
"    <span class=\"h3\">",
"     Clinicians&rsquo; personal awareness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative emotional reactions to patients (and consequent harmful behaviors) usually are not fully recognized by clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/30,38-41\">",
"     30,38-41",
"    </a>",
"    ]. These negative responses are the primary controllable determinants of the clinician-patient relationship and the key underlying problem when patients are perceived as difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/26,28-30,41-46\">",
"     26,28-30,41-46",
"    </a>",
"    ]. As an example, a patient repeatedly mentions his imminent death from carcinoma of the lung, but the doctor unwittingly avoids this discussion and notes only that she feels tense and anxious when the patient keeps mentioning death. This is a &ldquo;difficult patient&rdquo; she would prefer to avoid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/29,45\">",
"     29,45",
"    </a>",
"    ]. To the extent this clinician can become aware of her own unrecognized feelings (eg, personal fear of death, fear of discussing \"unpleasant\" topics, uncertainty what to do), she will work better with this patient and will be less likely to perceive him as difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/30,47,48\">",
"     30,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of these potentially harmful, unrecognized responses in clinicians and students are rare but needed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following observation of a learner-patient encounter, open-ended inquiry of learners showed that unrecognized responses with deleterious potential for the patient occurred in 13 of 15 students [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/28\">",
"       28",
"      </a>",
"      ] and 16 of 19 residents and fellows [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/50\">",
"       50",
"      </a>",
"      ]. This led the authors to propose that the majority of physicians and students have unrecognized, potentially harmful responses to patients. Common unrecognized feelings included: fear of losing control, addressing psychological material, appearing unpleasant, or harming the patient; unique personal issues (eg, reminds one of own difficult divorce, fear of cancer in self); and performance anxiety. Uncommon feelings included: sexual feelings; attitude favoring biomedical over psychosocial data; anger; fear of involvement; intimidation by the patient; inadequacy; disdain; identification with the patient. Severe anxiety and depressive feelings were not found. Common harmful and unrecognized behaviors included over control of the patient and interview (eg, inappropriate interrupting or changing subject), avoidance of psychological issues (eg, death, loneliness, disability), superficial behavior (eg, overly reassuring, overly social, &ldquo;cocktail party&rdquo; conversation), passivity (eg, no control or direction, inactive, detachment). Uncommon unrecognized behaviors included seductiveness, fault-finding, intimidation, passive-aggressiveness, lack of respect and sensitivity, withdrawal, distancing, and awkward interactions.",
"     </li>",
"     <li>",
"      In two other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/30,51\">",
"       30,51",
"      </a>",
"      ], an explicit method to teach self-awareness of unrecognized responses was used as part of teaching communication and doctor-patient relationship skills [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/30\">",
"       30",
"      </a>",
"      ]. As examples, learners were able to recognize and change previously unrecognized reactions (",
"      <a class=\"graphic graphic_table graphicRef79237 \" href=\"UTD.htm?15/62/16363\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These skills result in a better understanding of the patient, and enable clinicians to perceive patients as less difficult, allowing them to better address patient needs with compassion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all clinicians respond to individual patients in the same way. While descriptions of common features and medical conditions of &ldquo;difficult patients&rdquo; are instructive in general, the individual clinician's previously unrecognized responses determine the specifics. They determine which clinicians see which patients as difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5607156\">",
"    <span class=\"h3\">",
"     Clinicians&rsquo; personal characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinician factors associated with perceiving more patients as difficult include less experience [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/2\">",
"     2",
"    </a>",
"    ], female gender [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/1\">",
"     1",
"    </a>",
"    ], higher perceived workload, lower job satisfaction, a biomedical rather than biopsychosocial approach, and lack of communication skills training [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/7\">",
"     7",
"    </a>",
"    ]. Another study found the following factors associated with greater practice frustration: age &lt;40 years, work &gt;55 hours per week, and greater number of patients with psychosocial problems or substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/13\">",
"     13",
"    </a>",
"    ]. Communication skills training appears to be able to alter clinician attitudes and beliefs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19975823\">",
"    <span class=\"h2\">",
"     System characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should not bear sole blame for difficult clinician-patient interactions. The change in the healthcare environment in the United States over the past 20 years has contributed to an increase in patient and clinician frustrations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Competing demands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased productivity demands, attention to disease screening and health maintenance, disease complexity, and visit interruptions decrease the time for clinicians and patients to explore concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/9\">",
"     9",
"    </a>",
"    ]. This increases the risk of patients leaving the visit with unmet expectations and being dissatisfied with their care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/57\">",
"     57",
"    </a>",
"    ]. Dissatisfaction may then lead to increased patient demands and clinician frustration, which can create difficulty in the clinician-patient relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19975861\">",
"    <span class=\"h3\">",
"     Patient complexity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient complexity describes more than just medical comorbidities. It includes the patient&rsquo;s readiness to engage in healthcare; social factors such as stable, safe housing and effective social networking; health system factors such as multiple providers and distrust of the system; and care resources, including insurance and shared language [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/58\">",
"     58",
"    </a>",
"    ]. The healthcare delivery system has traditionally not been structured to assess for or effectively address patient complexity beyond disease complexity. For example, encounters spent addressing mental health concerns take longer and are remunerated less than those focused on biomedical issues [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     WORKING MORE EFFECTIVELY WITH THE DIFFICULT PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is apparent that, in addition to more training in communication skills and psychosocial medicine, the clinician must develop increased awareness of previously unrecognized, negative responses to &ldquo;difficult patients&rdquo; (",
"    <a class=\"graphic graphic_table graphicRef69677 \" href=\"UTD.htm?35/52/36683\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/38,41,44,46,60-63\">",
"     38,41,44,46,60-63",
"    </a>",
"    ]. Balint Groups (self-help groups of physicians to discuss difficult patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], meditation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], keeping a journal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/68-70\">",
"     68-70",
"    </a>",
"    ], reading and discussing relevant literature and poetry [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/71\">",
"     71",
"    </a>",
"    ], co-teaching with a mental health professional [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/30\">",
"     30",
"    </a>",
"    ], psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/44\">",
"     44",
"    </a>",
"    ], and special communication skill and personal awareness training (eg, American Academy on Communication in Healthcare courses:",
"    <a class=\"external\" href=\"file://www.aachonline.org/\">",
"     www.aachonline.org",
"    </a>",
"    ) all can be helpful. Raising consciousness of one's own emotions (eg, by reading or seeing movies about emotional topics) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21\">",
"     21",
"    </a>",
"    ] and obtaining feedback on one's communication skills [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/9\">",
"     9",
"    </a>",
"    ] are also useful.",
"   </p>",
"   <p>",
"    An evidence-based patient-centered interviewing method is particularly useful in difficult clinician-patient relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21\">",
"     21",
"    </a>",
"    ]. The keys are to understand the patient&rsquo;s perspective and to elicit the patient's emotions and respond empathically. Elicit the patient&rsquo;s perspective by asking what hopes the patient had before becoming ill, how the illness has affected the patient&rsquo;s life, and what losses have been experienced because of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/53\">",
"     53",
"    </a>",
"    ]. If emotion is not expressed, ask, &ldquo;How does this make you feel?&rdquo; and then express empathy by",
"    <strong>",
"     N",
"    </strong>",
"    aming it,",
"    <strong>",
"     U",
"    </strong>",
"    nderstanding it,",
"    <strong>",
"     R",
"    </strong>",
"    especting the patient, and",
"    <strong>",
"     S",
"    </strong>",
"    upporting the patient; that is, NURS the emotion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8249?source=see_link\">",
"     \"Patient-centered interviewing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With many distressed patients, especially those expressing anger or sadness, the empathy skills (NURS) will be needed many times, as will an understanding of the problem by using open-ended skills, such as echoing and summarizing. Considerations about the general approach to the patient are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12200?source=see_link\">",
"     \"Approach to the patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The salient feature of the individual difficult patient's personality should be identified; this information can then be used to enhance the relationship by \"going with the flow\" of the major thrust of the patient's personality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/21,72\">",
"     21,72",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With an obsessive patient, compliment him on his intellectuality, precision, and organization; avoid battles over control or pushing the patient for much emotion, which these patients usually like to avoid.",
"     </li>",
"     <li>",
"      With a dependent patient, the relationship is enhanced by meeting some of his special needs and not pushing him to be independent, while also establishing clear limits, such as length of office visits or frequency of unscheduled calls. Written instructions can reassure the patient that the clinician has an individualized care plan for him. Regularly scheduled visits will prevent these patients from &ldquo;manufacturing&rdquo; complaints in order to be seen. Over time, as the relationship is established, the clinician wants to facilitate the patient's more independent functioning.",
"     </li>",
"     <li>",
"      For the histrionic patient, the clinician can compliment him upon his flair, uniqueness, fun-loving nature, and attractive clothing and not use as much intellectual discussion as with an obsessive patient.",
"     </li>",
"     <li>",
"      For the self-defeating patient, the relationship is enhanced by simply acknowledging his plight and not trying to fix the situation.",
"     </li>",
"     <li>",
"      For the patient with borderline personality disorder, empathic acknowledgment of abandonment fears coupled with clear limit setting is an important part of the treatment plan [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/31,73\">",
"       31,73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"       \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Being self-aware and patient-centered and incorporating knowledge about the patient's personality are baseline requirements for working with difficult clinician-patient encounters. The clinician also must be prepared to apologize to the angry (or otherwise emotional) patient when that is in order (eg, waiting one hour to see the doctor) and acknowledge that problems exist and should be addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians must be skilled in identifying psychosocial problems [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/14\">",
"     14",
"    </a>",
"    ]. Problem-solving skills also are essential, as is a willingness to participate in the solution. The clinician often needs to function in many roles, including as an advocate, counselor, friend, disciplinarian, coach, or cheerleader. A difficult noncompliant diabetic patient might variously need some of the following: advocacy with the patient's spouse around his diet; counseling about issues not directly related to diabetes (marital problems); a friendly interaction and ongoing concern; a forthright talk about the need to better monitor his diabetes and adhere to diet; coaching about how to integrate diabetic treatment needs into a job with varying demands for exercise and dining with clients; and overt cheering for success with weight loss. Thus, the clinician is an active participant in care. This conveys genuine interest and concern.",
"   </p>",
"   <p>",
"    It is appropriate to be human and express discomfort and disappointment as well as joy, which can be done without manipulating, attacking the difficult patient personally, or making the patient unduly uncomfortable. The clinician might say to one patient, \"You know, I can't tell you how disappointed I am that your sugar has not come down one bit,\" and to another patient, \"I'm really proud of you and what we've done in getting this diabetes controlled. Good going!\"",
"   </p>",
"   <p>",
"    When difficult clinician-patient encounters weaken the clinician's self-esteem, it is important to recall that often the negativity is not personal, but rather a way certain patients express themselves. Being aware of transference and countertransference is also important [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/28,75\">",
"     28,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthcare environment improvements include assessing for patient complexity and developing appropriate (often multidisciplinary) action plans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/58,76,77\">",
"     58,76,77",
"    </a>",
"    ], establishing links to community mental health resources, altering scheduling systems to allow for more time for certain patients, and ensuring frequent, regular follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/9,55,56\">",
"     9,55,56",
"    </a>",
"    ]. Health system reforms to appropriately value cognitive work and time spent are also needed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23992/abstract/14,59\">",
"     14,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The &ldquo;difficult patient&rdquo; can be defined as one who impedes the clinician's ability to establish a therapeutic relationship. In other terms, such patients may have characteristics that conflict with the provider&rsquo;s beliefs and values and behaviors that challenge the providers&rsquo; competence or control. Characteristics of patients more likely to be considered difficult are shown in a table (",
"      <a class=\"graphic graphic_table graphicRef66724 \" href=\"UTD.htm?31/50/32555\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Factors contributing to difficult patient encounters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of clinician characteristics increase the likelihood of viewing patients as difficult (",
"      <a class=\"graphic graphic_table graphicRef67125 \" href=\"UTD.htm?0/61/987\">",
"       table 2",
"      </a>",
"      ). Clinicians typically receive limited psychosocial training and may be unaware of their own negative reactions to certain patients. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinician characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The healthcare system sets up competing demands that limit the time that may be needed by patients with complex psychosocial needs. (See",
"      <a class=\"local\" href=\"#H19975823\">",
"       'System characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Development of communication skills and improved self-awareness can help clinicians work more empathetically and effectively with difficult patients (",
"      <a class=\"graphic graphic_table graphicRef69677 \" href=\"UTD.htm?35/52/36683\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Working more effectively with the difficult patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/1\">",
"      An PG, Rabatin JS, Manwell LB, et al. Burden of difficult encounters in primary care: data from the minimizing error, maximizing outcomes study. Arch Intern Med 2009; 169:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/2\">",
"      Crutcher JE, Bass MJ. The difficult patient and the troubled physician. J Fam Pract 1980; 11:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/3\">",
"      Lin EH, Katon W, Von Korff M, et al. Frustrating patients: physician and patient perspectives among distressed high users of medical services. J Gen Intern Med 1991; 6:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/4\">",
"      Hahn SR, Thompson KS, Wills TA, et al. The difficult doctor-patient relationship: somatization, personality and psychopathology. J Clin Epidemiol 1994; 47:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/5\">",
"      Hahn SR, Kroenke K, Spitzer RL, et al. The difficult patient: prevalence, psychopathology, and functional impairment. J Gen Intern Med 1996; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/6\">",
"      Hahn SR. Physical symptoms and physician-experienced difficulty in the physician-patient relationship. Ann Intern Med 2001; 134:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/7\">",
"      Mathers N, Jones N, Hannay D. Heartsink patients: a study of their general practitioners. Br J Gen Pract 1995; 45:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/8\">",
"      Jackson JL, Kroenke K. Difficult patient encounters in the ambulatory clinic: clinical predictors and outcomes. Arch Intern Med 1999; 159:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/9\">",
"      Haas LJ, Leiser JP, Magill MK, Sanyer ON. Management of the difficult patient. Am Fam Physician 2005; 72:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/10\">",
"      John C, Schwenk TL, Roi LD, Cohen M. Medical care and demographic characteristics of 'difficult' patients. J Fam Pract 1987; 24:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/11\">",
"      Schwenk TL, Marquez JT, Lefever RD, Cohen M. Physician and patient determinants of difficult physician-patient relationships. J Fam Pract 1989; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/12\">",
"      Walker EA, Katon WJ, Keegan D, et al. Predictors of physician frustration in the care of patients with rheumatological complaints. Gen Hosp Psychiatry 1997; 19:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/13\">",
"      Krebs EE, Garrett JM, Konrad TR. The difficult doctor? Characteristics of physicians who report frustration with patients: an analysis of survey data. BMC Health Serv Res 2006; 6:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/14\">",
"      Kroenke K. Unburdening the difficult clinical encounter. Arch Intern Med 2009; 169:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/15\">",
"      Balla J, Heneghan C, Thompson M, Balla M. Clinical decision making in a high-risk primary care environment: a qualitative study in the UK. BMJ Open 2012; 2:e000414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/16\">",
"      Hinchey SA, Jackson JL. A cohort study assessing difficult patient encounters in a walk-in primary care clinic, predictors and outcomes. J Gen Intern Med 2011; 26:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/17\">",
"      Peteet JR, Meyer FL, Miovic MK. Possibly impossible patients: management of difficult behavior in oncology outpatients. J Oncol Pract 2011; 7:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/18\">",
"      Shapiro J, Astin J, Shapiro SL, et al. Coping with loss of control in the practice of medicine. Fam Syst Health 2011; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/19\">",
"      Slort W, Blankenstein AH, Deliens L, van der Horst HE. Facilitators and barriers for GP-patient communication in palliative care: a qualitative study among GPs, patients, and end-of-life consultants. Br J Gen Pract 2011; 61:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/20\">",
"      Steinmetz D, Tabenkin H. The 'difficult patient' as perceived by family physicians. Fam Pract 2001; 18:495.",
"     </a>",
"    </li>",
"    <li>",
"     Smith RC. Patient-Centered Interviewing: An Evidence-Based Method, 2nd ed, Lippincott Williams and Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/22\">",
"      Smith RC, Lyles JS, Gardiner JC, et al. Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial. J Gen Intern Med 2006; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/23\">",
"      Simon JR, Dwyer J, Goldfrank LR. The difficult patient. Emerg Med Clin North Am 1999; 17:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/24\">",
"      Macdonald M. Seeing the cage: stigma and its potential to inform the concept of the difficult patient. Clin Nurse Spec 2003; 17:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/25\">",
"      Lorber J. Good patients and problem patients: conformity and deviance in a general hospital. J Health Soc Behav 1975; 16:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/26\">",
"      Smith RC, Zimny GH. Physicians' emotional reactions to patients. Psychosomatics 1988; 29:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/27\">",
"      Katz RC. \"Difficult patients\" as family physicians perceive them. Psychol Rep 1996; 79:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/28\">",
"      Smith RC. Teaching interviewing skills to medical students: the issue of 'countertransference'. J Med Educ 1984; 59:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/29\">",
"      Maguire P, Faulkner A, Booth K, et al. Helping cancer patients disclose their concerns. Eur J Cancer 1996; 32A:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/30\">",
"      Smith RC, Dorsey AM, Lyles JS, Frankel RM. Teaching self-awareness enhances learning about patient-centered interviewing. Acad Med 1999; 74:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/31\">",
"      Gross R, Olfson M, Gameroff M, et al. Borderline personality disorder in primary care. Arch Intern Med 2002; 162:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/32\">",
"      Gabbard GO. The role of compulsiveness in the normal physician. JAMA 1985; 254:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/33\">",
"      Wetterneck TB, Linzer M, McMurray JE, et al. Worklife and satisfaction of general internists. Arch Intern Med 2002; 162:649.",
"     </a>",
"    </li>",
"    <li>",
"     Ford CV. The somatizing disorders: Illness as a way of life, Elsevier Biomedical, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/35\">",
"      Katon W, Ries RK, Kleinman A. The prevalence of somatization in primary care. Compr Psychiatry 1984; 25:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/36\">",
"      Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med 1989; 86:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/37\">",
"      Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry 1998; 59 Suppl 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/38\">",
"      Smith RC, Dwamena FC, Fortin AH 6th. Teaching personal awareness. J Gen Intern Med 2005; 20:201.",
"     </a>",
"    </li>",
"    <li>",
"     Stein HF. The Psychodynamics of Medical Practice, University of California Press, Berkeley 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/40\">",
"      KERNBERG O. THE CONCEPT OF COUNTERTRANSFERENCE. J Am Psychoanal Assoc 1965; 13:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/41\">",
"      Marshall AA, Smith RC. Physicians' emotional reactions to patients: recognizing and managing countertransference. Am J Gastroenterol 1995; 90:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/42\">",
"      Gorlin R, Strain J, Rhodes R. Physicians' reactions to patients: what has happened during the past 10 years. Mt Sinai J Med 1996; 63:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/43\">",
"      Johnson AH. Assessing counseling skills and attitudes in family practice residents. J Fam Pract 1979; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/44\">",
"      Novack DH, Suchman AL, Clark W, et al. Calibrating the physician. Personal awareness and effective patient care. Working Group on Promoting Physician Personal Awareness, American Academy on Physician and Patient. JAMA 1997; 278:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/45\">",
"      Maguire P. Barriers to psychological care of the dying. Br Med J (Clin Res Ed) 1985; 291:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/46\">",
"      Novack DH, Epstein RM, Paulsen RH. Toward creating physician-healers: fostering medical students' self-awareness, personal growth, and well-being. Acad Med 1999; 74:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/47\">",
"      Barsky AJ. The paradox of health. N Engl J Med 1988; 318:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/48\">",
"      Lesse S. Depression masked by acting-out behavior patterns. Am J Psychother 1974; 28:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/49\">",
"      Hall JA. Some observations on provider-patient communication research. Patient Educ Couns 2003; 50:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/50\">",
"      Smith RC. Unrecognized responses and feelings of residents and fellows during interviews of patients. J Med Educ 1986; 61:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/51\">",
"      Smith RC, Osborn G, Hoppe RB, et al. Efficacy of a one-month training block in psychosocial medicine for residents: a controlled study. J Gen Intern Med 1991; 6:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/52\">",
"      Kahn MW. What would Osler do? Learning from \"difficult\" patients. N Engl J Med 2009; 361:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/53\">",
"      Breuner CC, Moreno MA. Approaches to the difficult patient/parent encounter. Pediatrics 2011; 127:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/54\">",
"      Jenkins V, Fallowfield L. Can communication skills training alter physicians' beliefs and behavior in clinics? J Clin Oncol 2002; 20:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/55\">",
"      Nutting PA, Rost K, Smith J, et al. Competing demands from physical problems: effect on initiating and completing depression care over 6 months. Arch Fam Med 2000; 9:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/56\">",
"      Rost K, Nutting P, Smith J, et al. The role of competing demands in the treatment provided primary care patients with major depression. Arch Fam Med 2000; 9:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/57\">",
"      Jackson JL, Kroenke K. The effect of unmet expectations among adults presenting with physical symptoms. Ann Intern Med 2001; 134:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/58\">",
"      Peek CJ, Baird MA, Coleman E. Primary care for patient complexity, not only disease. Fam Syst Health 2009; 27:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/59\">",
"      Meadows T, Valleley R, Haack MK, et al. Physician \"costs\" in providing behavioral health in primary care. Clin Pediatr (Phila) 2011; 50:447.",
"     </a>",
"    </li>",
"    <li>",
"     Smith RC. The patient's story: integrated patient-doctor interviewing, Little Brown, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/61\">",
"      Maguire P, Faulkner A. Improve the counselling skills of doctors and nurses in cancer care. BMJ 1988; 297:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/62\">",
"      Quill TE. Recognizing and adjusting to barriers in doctor-patient communication. Ann Intern Med 1989; 111:51.",
"     </a>",
"    </li>",
"    <li>",
"     Platt FW, Gordon GH. Field Guide to the Difficult Patient Interview, Lipincott, Williams &amp; Wilkins, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/64\">",
"      Scheingold L. Balint work in England: lessons for American family medicine. J Fam Pract 1988; 26:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/65\">",
"      Courtenay, MJ. A plain doctor's guide to Balint-work. Journal Balint Society 1992; 20:20.",
"     </a>",
"    </li>",
"    <li>",
"     Kabat-Zinn J. Wherever You Go, There You Are: Mindfulness Meditation in Everyday Life, Hyperion, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/67\">",
"      Epstein RM. Mindful practice. JAMA 1999; 282:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/68\">",
"      Smyth JM, Stone AA, Hurewitz A, Kaell A. Effects of writing about stressful experiences on symptom reduction in patients with asthma or rheumatoid arthritis: a randomized trial. JAMA 1999; 281:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/69\">",
"      Watson D, Pennebaker JW. Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev 1989; 96:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/70\">",
"      Pennebaker JW, Colder M, Sharp LK. Accelerating the coping process. J Pers Soc Psychol 1990; 58:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/71\">",
"      Shapiro J, Lie D. Using literature to help physician-learners understand and manage \"difficult\" patients. Acad Med 2000; 75:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/72\">",
"      Ferrando SJ, Okoli U. Personality disorders: understanding and managing the difficult patient in neurology practice. Semin Neurol 2009; 29:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/73\">",
"      American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001; 158:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/74\">",
"      McCord RS, Floyd MR, Lang F, Young VK. Responding effectively to patient anger directed at the physician. Fam Med 2002; 34:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/75\">",
"      Goldberg PE. The physician-patient relationship: three psychodynamic concepts that can be applied to primary care. Arch Fam Med 2000; 9:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/76\">",
"      Huyse FJ, Stiefel FC, de Jonge P. Identifiers, or \"red flags,\" of complexity and need for integrated care. Med Clin North Am 2006; 90:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23992/abstract/77\">",
"      Stiefel FC, Huyse FJ, S&ouml;llner W, et al. Operationalizing integrated care on a clinical level: the INTERMED project. Med Clin North Am 2006; 90:713.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2764 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23992=[""].join("\n");
var outline_f23_27_23992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS CONTRIBUTING TO DIFFICULT PATIENT ENCOUNTERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Patients' expressions of emotions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Patients' personality features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Patients' personal characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Patients' specific clinical problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Patients' direct demands/stresses on the clinician",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinician characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5606995\">",
"      - Clinicians' psychosocial training",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5607123\">",
"      - Clinicians&rsquo; personal awareness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5607156\">",
"      - Clinicians&rsquo; personal characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19975823\">",
"      System characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Competing demands",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19975861\">",
"      - Patient complexity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      WORKING MORE EFFECTIVELY WITH THE DIFFICULT PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2764|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/50/32555\" title=\"table 1\">",
"      Difficult patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/61/987\" title=\"table 2\">",
"      Clinician factors difficult patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/62/16363\" title=\"table 3\">",
"      Clinician personal awareness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/52/36683\" title=\"table 4\">",
"      Reduce difficult patient burdens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12200?source=related_link\">",
"      Approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=related_link\">",
"      Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8249?source=related_link\">",
"      Patient-centered interviewing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=related_link\">",
"      Primary care management of medically unexplained symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_27_23993="Pleural effusions in HIV-infected patients";
var content_f23_27_23993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pleural effusions in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23993/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23993/contributors\">",
"     Jose Joseph, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23993/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23993/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23993/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23993/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/27/23993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are frequently encountered in patients with acquired immunodeficiency syndrome (AIDS). The prevalence of pleural effusion in hospitalized patients with AIDS varies from 7 to 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The variations in prevalence may be explained by differences in the clinical stage of AIDS and the techniques used in detecting pleural effusion.",
"   </p>",
"   <p>",
"    The majority of pleural effusions in patients with HIV infection are caused by infections; however, about a third are due to noninfectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2\">",
"     2",
"    </a>",
"    ]. Now that viral infections appear responsible for some of the malignant effusions (eg, Kaposi sarcoma, multicentric Castleman's disease, primary effusion lymphoma), the line between infectious and noninfectious causes is blurred. In addition, much of the data regarding prevalence comes from hospitalized patients with advanced HIV infection in the pre-highly active retroviral therapy (HAART) era and may not reflect the post-HAART experience.",
"   </p>",
"   <p>",
"    The etiology of the pleural effusion can be established in the majority of patients with AIDS, although a small percentage remains undiagnosed, as is the case in the non-AIDS population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The common causes of pleural effusions in patients with HIV infection are reviewed here. The general approach to the investigation of a pleural effusion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTIOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HIV infection, many of the same infectious agents that cause pneumonia should be considered as potential etiologies of pleural effusion (",
"    <a class=\"graphic graphic_table graphicRef58777 graphicRef71626 \" href=\"UTD.htm?18/20/18766\">",
"     table 1A-B",
"    </a>",
"    ). Among studies of hospitalized patients with a pleural effusion and HIV infection, an infectious etiology was identified in about two-thirds [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In general, opportunistic infections of the pleura should be considered in patients with a CD4 count below 150 cells per microL, as these patients have an increased risk of opportunistic infection, possibly approaching that of preHAART patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial pneumonia was the most common cause of pleural effusion in AIDS, accounting for approximately 30 percent of effusions in three series of hospitalized patients with AIDS in the pre-HAART era [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a series of 137 patients with community-acquired pneumonia, HIV-infected patients had a higher rate of parapneumonic effusions than non-HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/4\">",
"     4",
"    </a>",
"    ]. With the introduction of HAART, the incidence of bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/5\">",
"     5",
"    </a>",
"    ] and the complication of parapneumonic effusion have decreased in HIV infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these parapneumonic effusions are small and ipsilateral to the side of the pneumonia. The fluid is exudative and generally nucleated cell counts are low. Although relatively uncommon, empyema has been observed in 11 percent of parapneumonic effusions in AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Streptococcus pneumoniae accounts for more than 50 percent of these parapneumonic effusions; Staphylococcus aureus is the next most common etiologic organism. Less frequent causes include Haemophilus influenzae, Mycoplasma pneumoniae, Legionella, Nocardia asteroides, and Bordetella bronchiseptica [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Septic pulmonary embolization from right-sided endocarditis in intravenous drug abusers can also result in small pleural effusions.",
"   </p>",
"   <p>",
"    Treatment of bacterial pneumonia in HIV-infected patients is discussed separately. Uncomplicated parapneumonic effusions generally resolve with treatment of the underlying pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=see_link\">",
"     \"Bacterial pulmonary infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pneumocystis jirovecii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis jirovecii pneumonia (PCP) remains an uncommon cause of pleural effusion in HIV-infected patients, with an incidence varying from 3 to 15 percent in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Based on a small case series, there is a suggestion that pleural effusion due to PCP occurs more commonly in patients receiving aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition to pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], PCP also is associated with pleural masses and pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1,13-15\">",
"     1,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleural effusions due to PCP are usually small to moderate in size; can be either unilateral or bilateral; and are serous to bloody in appearance. Pleural fluid acidosis (ie, pH &lt;7.50) has not been reported. LDH is elevated, with a pleural fluid to serum ratio greater than 1, characterizing the fluid as an exudate. Total protein pleural fluid to serum ratio tends to be less than 0.5, and pleural fluid glucose and amylase are equivalent to serum values [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/9\">",
"     9",
"    </a>",
"    ]. The total nucleated cell count is low, and the differential shows predominantly mononuclear cells.",
"   </p>",
"   <p>",
"    A definitive diagnosis requires demonstration of the trophozoite or cyst forms of Pneumocystis in the pleural fluid. Grocott silver staining will show the cysts; however, if the pleural fluid has predominantly trophozoite forms, silver stain may not be sufficiently sensitive to establish the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/10\">",
"     10",
"    </a>",
"    ]. In such cases, examination of an air-dried Diff-Quik stained cytospin preparation is ideal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other markers of Pneumocystis pleural infection are the presence of granular eosinophilic aggregates, numerous vacuolated macrophages, and scattered benign mesothelial cell clusters in the pleural fluid. The diagnosis of pleural effusion due to Pneumocystis can be made presumptively if the organisms are identified in bronchoalveolar lavage (BAL) fluid and the effusion resolves following treatment for PCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither the treatment nor the prognosis of PCP is altered by the development of a pleural effusion. On the other hand, the development of pneumothorax in these patients is often an ominous occurrence, and usually signals the need for prolonged chest tube drainage.",
"   </p>",
"   <p>",
"    The treatment of P jirovecii in HIV-infected patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"     \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterial infection accounts for 8 to 10 percent of pleural effusions in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In most series, Mycobacterium tuberculosis (TB) was found to cause pleuritis more often than Mycobacterium avium complex (MAC); however, one study of 130 patients found the opposite in that 6 percent of HIV related effusions were due to MAC and 1 percent to TB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2,3,6,16\">",
"     2,3,6,16",
"    </a>",
"    ]. Other nontuberculous mycobacteria rarely cause pleural disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/17\">",
"     17",
"    </a>",
"    ]. A discussion of the diagnosis and treatment of tuberculous pleurisy in HIV-infected patients is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural TB may occur with or without visible lung parenchymal disease. In a series of 70 patients with HIV infection and pleural TB, the chest radiograph showed an isolated pleural effusion, associated pulmonary parenchymal infiltrate, and a miliary pattern in 51, 37, and 8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/18\">",
"     18",
"    </a>",
"    ]. In a case report, a pleural effusion due to MAC infection was large enough to cause hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pleural effusion is virtually always exudative and usually demonstrates neither pleural fluid acidosis nor low glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/20\">",
"     20",
"    </a>",
"    ]. The nucleated cell counts in the pleural fluid are lower than that seen in TB pleurisy of HIV-uninfected patients; a predominance of lymphocytes is usually noted. Pleural fluid lymphocytes and CD14 positive macrophages have been shown to be a sanctuary for increased HIV replication in patients with Mycobacterium tuberculosis pleurisy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other diagnostic tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      (PPD) is positive in 20 to 64 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/18,22\">",
"       18,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pleural fluid adenosine deaminase (ADA) is typically greater than 50",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      in tuberculous pleural effusions, independent of HIV status [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sputum acid-fast smear is positive more often in HIV-infected patients with advanced immunodeficiency compared to those with relatively preserved CD4 cells counts [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/18,22\">",
"       18,22",
"      </a>",
"      ]. Sputum induction may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The pleural fluid acid-fast smear is positive in less than 15 percent of tuberculous effusions.",
"     </li>",
"     <li>",
"      Pleural biopsy for acid-fast stain and pathologic examination for granulomas is helpful with yields better than 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/18,20\">",
"       18,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of TB in HIV-infected patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immune reconstitution inflammatory syndrome (IRIS) refers to paradoxical worsening of systemic inflammation associated with preexisting infectious processes following the initiation of highly active antiretroviral therapy (HAART) in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/25\">",
"     25",
"    </a>",
"    ]. This is more likely to occur in patients with a CD4 count under 100 cells per microL and in the setting of initiation of TB treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Patients may present with worsening constitutional symptoms, pulmonary parenchymal disease, adenopathy, or pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nocardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocardia asteroides has been identified in about 3 percent of pleural effusions in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2,28,29\">",
"     2,28,29",
"    </a>",
"    ]. It is generally associated with more advanced AIDS. The evaluation and treatment of nocardia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cryptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcus neoformans can occasionally cause pleural effusions in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/30\">",
"     30",
"    </a>",
"    ]. An isolated pleural effusion may be the initial manifestation of disseminated cryptococcal disease in AIDS, whereas it usually occurs in association with pulmonary parenchymal disease in the non-AIDS population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2,31-34\">",
"     2,31-34",
"    </a>",
"    ]. C. laurentii, another strain of cryptococcus, has been also identified as a causative agent for pleural effusion in AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cryptococcal effusions, the pleural fluid is typically a serous exudate with a low nucleated cell count. Pleural fluid culture is diagnostic in 42 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/36\">",
"     36",
"    </a>",
"    ]. Cryptococcal antigen determination in pleural fluid of non-AIDS patients has proved to be a rapid and specific test [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/37\">",
"     37",
"    </a>",
"    ]. Therefore, serum and pleural fluid cryptococcal antigen tests should be performed in all AIDS patients with pleural effusion, since a positive result may allow early treatment and prevent dissemination. Pleural fluid culture is usually positive within a week; however, an incubation time up to two weeks may be necessary before a fluid sample is considered negative for Cryptococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/33\">",
"     33",
"    </a>",
"    ]. Pleural biopsy has been helpful in making a definite diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/33\">",
"     33",
"    </a>",
"    ]. Pleural fluid adenosine deaminase concentration has been reported to be falsely elevated in cryptococcal pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/38\">",
"     38",
"    </a>",
"    ]. The pleural effusion resolves with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , but may also resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other rare causes for pleural effusion in AIDS worldwide include: paracoccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/40\">",
"     40",
"    </a>",
"    ] and filariasis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40756?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histoplasma capsulatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated histoplasmosis is an important opportunistic infection in AIDS; however, Histoplasma capsulatum is rarely a cause of pleural effusion in patients with or without AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/36,42\">",
"     36,42",
"    </a>",
"    ]. Histoplasma pleural effusion can occur in association with dissemination, contiguous spread, hypersensitivity pleuritis, or active pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effusion is serous or serosanguineous, with a low number of nucleated cells. A cytocentrifuged pleural fluid specimen stained with Wright-Giemsa stain will demonstrate intracellular yeast typical of Histoplasma capsulatum. The pleural effusion usually resolves without treatment; however, resolution may be slow, over several months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Toxoplasma gondii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma gondii is a rare cause of pleural effusion that occurs in the late stages of AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/43\">",
"     43",
"    </a>",
"    ]. Pleural effusion may be unilateral or bilateral. A cytocentrifuged Wright-Giemsa-stained specimen of pleural fluid will demonstrate T. gondii tachyzoites within neutrophils. Tachyzoites can also be found in bronchoalveolar lavage fluid when there is concomitant pulmonary parenchymal disease.",
"   </p>",
"   <p>",
"    The treatment of pulmonary T. gondii infection in HIV-infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Leishmaniasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral leishmaniasis is a common infection in patients with AIDS who live in endemic areas. Rare cases of pleural effusion have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42308?source=see_link\">",
"     \"Epidemiology and control of visceral leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21161?source=see_link\">",
"     \"Clinical manifestations and diagnosis of visceral leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=see_link\">",
"     \"Treatment of visceral leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MALIGNANT EFFUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients have an increased propensity to develop malignancies that cause pleural effusions, particularly if their CD4 count is below",
"    <span class=\"nowrap\">",
"     200/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58777 graphicRef71626 \" href=\"UTD.htm?18/20/18766\">",
"     table 1A-B",
"    </a>",
"    ). Some of these (eg, Kaposi sarcoma, multicentric Castleman's disease, primary effusion lymphoma [PEL]) are related to infections with human herpes virus 8 (HHV8)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Epstein Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with AIDS infection also develop other cancers that may cause pleural effusions; these are reviewed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Kaposi sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusion occurs in 36 to 60 percent of patients with Kaposi's sarcoma (KS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The onset of pleural effusion is preceded by appearance of cutaneous KS lesions by several months (",
"    <a class=\"graphic graphic_picture graphicRef75375 graphicRef79013 graphicRef69203 \" href=\"UTD.htm?8/15/8441\">",
"     picture 1A-C",
"    </a>",
"    ), and usually by a fall in CD4 count to below 150 cells per microL and an increase in viral load to above 10,000 copies per mL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/48\">",
"     48",
"    </a>",
"    ]. Although there is generally a poor correlation between the extent of skin lesions and involvement of internal organs, thoracic KS rarely occurs without skin lesions. Pleuritic chest pain is absent because the visceral pleura is involved, not the parietal pleura. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=see_link\">",
"     \"Pulmonary involvement in AIDS-related Kaposi sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the pleural effusion, the chest radiograph typically shows unilateral or bilateral interstitial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alveolar infiltrates; hilar or mediastinal adenopathy is present in 25 to 60 percent of patients with pleuropulmonary Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Pleural effusions are predominantly bilateral and are large to massive in size (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87395 \" href=\"UTD.htm?41/38/42593\">",
"     image 1",
"    </a>",
"    ). Pleural fluid was serosanguineous and free flowing in a majority of patients; hemorrhagic effusions are also seen.",
"   </p>",
"   <p>",
"    In a review of 105 postmortem examinations of patients with KS, thoracic findings included bilateral hemorrhagic pleural effusions, purplish lesions of Kaposi's sarcoma on the visceral pleura, and infiltration of lung parenchymal lymphatics and mediastinal lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/46\">",
"     46",
"    </a>",
"    ]. Effusions are typically serosanguineous due to hemorrhage from highly vascular lesions of the visceral pleura.",
"   </p>",
"   <p>",
"    Pleural fluid characteristics are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nucleated cell counts are generally low, and there is mononuclear cell predominance",
"     </li>",
"     <li>",
"      The fluid is exudative",
"     </li>",
"     <li>",
"      The pH is usually greater than 7.44",
"     </li>",
"     <li>",
"      The LDH varies between 111 and 330",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"     </li>",
"     <li>",
"      The pleural fluid glucose concentration is greater than 60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Cytologic examination of the pleural fluid is unrewarding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chylous effusions have been increasingly recognized in KS, but the hemorrhagic nature of the effusion may mask the typical appearance of a chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/46,49\">",
"     46,49",
"    </a>",
"    ]. Pleural fluid triglyceride concentration will suggest the presence of a chylous effusion if it is greater than 110",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    however, the presence of chylomicrons is required for the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of pleural KS cannot be made by percutaneous pleural biopsy, because the lesions are not found on the parietal pleura. Although open lung biopsy establishes the diagnosis in 75 percent of cases, the high",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio makes this procedure of limited value [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/50\">",
"     50",
"    </a>",
"    ]. The finding of characteristic cherry-red endobronchial lesions on bronchoscopy essentially establishes the diagnosis of pleural Kaposi's sarcoma in the proper clinical setting, such as a patient with bilateral hemorrhagic effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effusions from KS often need drainage for symptomatic relief; the use of repeated thoracentesis is favored over more aggressive procedures in this setting.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    pleurodesis was ineffective in a limited number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/46\">",
"     46",
"    </a>",
"    ]. Radiation therapy has been used as a palliative measure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/51\">",
"     51",
"    </a>",
"    ]. A single case report indicated resolution of pleural and pericardial effusion following therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    , pleural drainage, and one session of whole lung irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .) The general treatment of KS is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About two-thirds of patients with KS associated with the immune reconstitution inflammatory syndrome (IRIS) will have pleural effusions, following initiation of highly active antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/53\">",
"     53",
"    </a>",
"    ]. The management of IRIS is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Multicentric Castleman's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicentric Castleman's disease (MCD) is a lymphoproliferative disorder that is highly associated with HIV and human herpes virus 8 (HHV8) infection. Typical pulmonary findings are reticular or nodular pulmonary parenchymal opacities, mediastinal adenopathy and, less commonly, bilateral pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/54\">",
"     54",
"    </a>",
"    ]. The diagnosis is usually made on a lymph node biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H10#H10\">",
"     \"Castleman's disease\", section on 'Multicentric Castleman's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-cell, non-Hodgkin lymphoma (NHL) occurs in 5 to 10 percent of patients with AIDS. The reported prevalence of lymphoma related pleural effusion varies from 1 to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/3,16,55\">",
"     3,16,55",
"    </a>",
"    ]. However, an autopsy series documented pleural effusion in 65 percent of those with thoracic involvement and in about 25 percent of all patients with NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 38 patients with pulmonary involvement from AIDS-related, non-Hodgkin lymphoma, advanced HIV infection was common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/56\">",
"     56",
"    </a>",
"    ]. Peripheral lymphadenopathy, hepatosplenomegaly, and elevated serum lactic dehydrogenase (LDH) were common. Pleural effusions were associated with pulmonary nodules, areas of consolidation, or masses; about 60 percent had associated thoracic lymphadenopathy. Pleural effusions caused by NHL may have a mass effect, whereas effusions from primary effusion lymphoma do not. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Primary effusion lymphoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When NHL involves the pleura, effusions tend to be large, serosanguineous, lymphocyte-predominant exudates with a normal glucose, and a high LDH concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/56\">",
"     56",
"    </a>",
"    ]. Pleural fluid cytology has been reported to be diagnostic in about 60 to 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Pleural biopsy also had a high diagnostic yield [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/56\">",
"     56",
"    </a>",
"    ]; flow cytometric examination of pleural fluid has also been useful in establishing the diagnosis in problematic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of non-Hodgkin lymphoma in HIV infected patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Primary effusion lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary effusion lymphoma (PEL) is a high-grade non-Hodgkin lymphoma (NHL) of B-cell origin that is predominantly found in HIV-seropositive homosexual men between the ages of 30 and 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. PEL is strongly associated with HHV8 infection. Preexisting Kaposi's sarcoma has been reported in about 33 percent of patients with PEL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PEL cell lines have been shown to generate excessive vascular endothelial growth factor",
"    <span class=\"nowrap\">",
"     (VEGF)/vascular",
"    </span>",
"    permeability factor (VPF);",
"    <span class=\"nowrap\">",
"     VEGF/VPF",
"    </span>",
"    may contribute to excessive fluid formation in the pleural space, pericardial sac, and abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/63\">",
"     63",
"    </a>",
"    ]. The absence of lymphadenopathy suggests that central lymphatic obstruction by lymphoma is not the mechanism for fluid formation.",
"   </p>",
"   <p>",
"    Thoracic computed tomography (CT) shows pleural effusion with adjacent parietal pleural thickening in the absence of lung parenchymal lesions or mediastinal lymphadenopathy. Pericardial effusion and ascites are other common radiological findings. Peripheral lymphadenopathy and bone marrow involvement are unusual findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of PEL is usually made by the cytologic examination of pleural fluid (",
"    <a class=\"graphic graphic_picture graphicRef58183 \" href=\"UTD.htm?42/40/43656\">",
"     picture 2",
"    </a>",
"    ). Pleural fluid immunocytochemistry shows malignant cells that are often positive for CD45 and CD30, and variable for epithelial membrane antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The nuclei usually stain positive for human herpes virus 8 (HHV-8); the most common method for detecting HHV-8 positivity is immunohistochemical staining for the latent viral gene product known as latency-associated nuclear antigen (LANA-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of PEL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lung cancer is significantly increased in patients with HIV infection, and malignant pleural effusions are a relatively common sequela of lung cancer in patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506361#H1560506361\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Lung cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER NONINFECTIOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other noninfectious disorders that may cause pleural effusions in HIV-infected patients include hypoalbuminemia, heart failure, uremia, and pulmonary embolism (",
"    <a class=\"graphic graphic_table graphicRef58777 graphicRef71626 \" href=\"UTD.htm?18/20/18766\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypoalbuminemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoalbuminemia has been encountered as a cause for pleural effusion in 7 to 15 percent of hospitalized patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Because hypoalbuminemia is a recognized problem in progressive AIDS, hypoalbuminemic pleural effusions may become more prevalent as the infectious complications of AIDS are managed more effectively. Hypoalbuminemic effusions are small to moderate in size, bilateral, and transudative. The nucleated cell count is low and mononuclear cells predominate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusion secondary to cardiac failure has been noted in hospitalized patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/2\">",
"     2",
"    </a>",
"    ]. In this setting, dilated cardiomyopathy is usually caused by infectious myocarditis; toxoplasmosis, cytomegalovirus, and HIV have all been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23993/abstract/68\">",
"     68",
"    </a>",
"    ]. Pleural effusions are small, unilateral or bilateral, and transudative. The effusions generally are clinically unimportant and resolve with treatment of the heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=see_link\">",
"     \"Cardiac involvement in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of pleural effusions in HIV-infected patients follows a similar algorithm to that for HIV-noninfected patients; however certain additional tests may be important (",
"    <a class=\"graphic graphic_table graphicRef58777 graphicRef71626 \" href=\"UTD.htm?18/20/18766\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .) If these tests are not diagnostic, further investigation should follow the steps for an undiagnosed pleural effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of pleural effusions in patients with AIDS are secondary to infection; however, about a third are due to non-infectious causes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial pneumonia is the single most common cause of pleural effusion in AIDS, accounting for approximately 30 percent of effusions in hospitalized AIDS patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Bacterial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleural effusion is an unusual manifestation of Pneumocystis jirovecii (PCP) infection in HIV-infected patients. PCP pleural effusions are usually small to moderate in size, either unilateral or bilateral, and serous to bloody in appearance. Trophozoite or cyst forms of P. jirovecii are found on Diff-Quik or silver stains of pleural fluid, respectively. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pneumocystis jirovecii'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mycobacterial infection accounts for 8 to 10 percent of pleural effusions in patients with AIDS; depending on the patient population, M. tuberculosis or M. avium complex may be more common. Acid-fast stain is positive in 15 percent of pleural fluid samples and 69 percent of pleural biopsy specimens; granulomas are present in up to 88 percent of the biopsies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mycobacteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other opportunistic infections may occasionally cause pleural effusions in HIV-infected patients, including Cryptococcus, Histoplasmosis, and Toxoplasma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Infectious causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleural effusions are common among patients with Kaposi's sarcoma (KS); the fluid is usually serosanguineous to hemorrhagic. Virtually all patients have skin lesions of KS and many have endobronchial KS. Pleural cytology and pleural biopsy are negative. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Kaposi sarcoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When systemic non-Hodgkin lymphoma involves the pleura, concomitant pulmonary nodules, masses, or consolidation are also present on computed tomography; about 60 percent of patients have mediastinal lymphadenopathy. Pleural fluid cytology and flow cytometry, pleural biopsy, and transbronchial biopsy of lung lesions have high diagnostic yields. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary effusion lymphoma (PEL) is a high-grade non-Hodgkin lymphoma (NHL) of B-cell origin. Unlike pleural effusions from MCD and other lymphomas, there is no associated lymphadenopathy. The diagnosis of PEL is usually made by the cytologic examination of pleural fluid with immunohistochemical staining for HHV8, such as the viral gene product, latency-associated nuclear antigen (LANA-1). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Primary effusion lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other noninfectious disorders that may cause pleural effusions in HIV-infected patients include hypoalbuminemia, heart failure, and pulmonary embolism. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Other noninfectious causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation of pleural effusions in HIV-infected patients follows a similar algorithm to that for HIV-noninfected patients; however certain additional tests may be important. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"       \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/1\">",
"      Afessa B. Pleural effusion and pneumothorax in hospitalized patients with HIV infection: the Pulmonary Complications, ICU support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/2\">",
"      Joseph J, Strange C, Sahn SA. Pleural effusions in hospitalized patients with AIDS. Ann Intern Med 1993; 118:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/3\">",
"      Armbruster C, Schalleschak J, Vetter N, Pokieser L. Pleural effusions in human immunodeficiency virus-infected patients. Correlation with concomitant pulmonary diseases. Acta Cytol 1995; 39:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/4\">",
"      Gil Suay V, Cordero PJ, Mart&iacute;nez E, et al. Parapneumonic effusions secondary to community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Eur Respir J 1995; 8:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/5\">",
"      Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/6\">",
"      Schlossbauer T, Schmidt GP, Bogner JR, et al. Pulmonary radiological characteristics in patients with HIV infection at the time of highly active antiretroviral therapy (HAART). Eur J Med Res 2007; 12:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/7\">",
"      Coker RJ. Empyema thoracis in AIDS. J R Soc Med 1994; 87:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/8\">",
"      Viejo G, de la Iglesia P, Otero L, et al. Bordetella bronchiseptica pleural infection in a patient with AIDS. Scand J Infect Dis 2002; 34:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/9\">",
"      Horowitz ML, Schiff M, Samuels J, et al. Pneumocystis carinii pleural effusion. Pathogenesis and pleural fluid analysis. Am Rev Respir Dis 1993; 148:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/10\">",
"      Balachandran I, Jones DB, Humphrey DM. A case of Pneumocystis carinii in pleural fluid with cytologic, histologic and ultrastructural documentation. Acta Cytol 1990; 34:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/11\">",
"      Elwood LJ, Dobrzanski D, Feuerstein IM, Solomon D. Pneumocystis carinii in pleural fluid. The cytologic appearance. Acta Cytol 1991; 35:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/12\">",
"      Jayes RL, Kamerow HN, Hasselquist SM, et al. Disseminated pneumocystosis presenting as a pleural effusion. Chest 1993; 103:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/13\">",
"      Abati AD, Opitz L, Brones C, et al. Cytology of extrapulmonary Pneumocystis carinii infection in the acquired immunodeficiency syndrome. Acta Cytol 1992; 36:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/14\">",
"      Beers MF, Sohn M, Swartz M. Recurrent pneumothorax in AIDS patients with Pneumocystis pneumonia. A clinicopathologic report of three cases and review of the literature. Chest 1990; 98:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/15\">",
"      Dyner TS, Lang W, Busch DF, Gordon PR. Intravascular and pleural involvement by Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 111:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/16\">",
"      Soubani AO, Michelson MK, Karnik A. Pleural fluid findings in patients with the acquired immunodeficiency syndrome: correlation with concomitant pulmonary disease. South Med J 1999; 92:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/17\">",
"      Koh WJ, Yu CM, Suh GY, et al. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int J Tuberc Lung Dis 2006; 10:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/18\">",
"      Relkin F, Aranda CP, Garay SM, et al. Pleural tuberculosis and HIV infection. Chest 1994; 105:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/19\">",
"      Kapetanopoulos A, Habboub A, Gillam LD, Ross JW. Cardiac tamponade as a result of Mycobacterium avium-complex pleural effusion. Conn Med 2004; 68:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/20\">",
"      Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007; 131:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/21\">",
"      Lawn SD, Pisell TL, Hirsch CS, et al. Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 2001; 184:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/22\">",
"      Kitinya JN, Richter C, Perenboom R, et al. Influence of HIV status on pathological changes in tuberculous pleuritis. Tuber Lung Dis 1994; 75:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/23\">",
"      Riantawan P, Chaowalit P, Wongsangiem M, Rojanaraweewong P. Diagnostic value of pleural fluid adenosine deaminase in tuberculous pleuritis with reference to HIV coinfection and a Bayesian analysis. Chest 1999; 116:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/24\">",
"      Conde MB, Loivos AC, Rezende VM, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med 2003; 167:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/25\">",
"      Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/26\">",
"      Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/27\">",
"      Buckingham SJ, Haddow LJ, Shaw PJ, Miller RF. Immune reconstitution inflammatory syndrome in HIV-infected patients with mycobacterial infections starting highly active anti-retroviral therapy. Clin Radiol 2004; 59:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/28\">",
"      Uttamchandani RB, Daikos GL, Reyes RR, et al. Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. Clin Infect Dis 1994; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/29\">",
"      Inthraburan K, Wongsa A. Empyema thoracis due to nocardiosis and Mycobacterium tuberculosis mixed infections in an AIDS patient. Southeast Asian J Trop Med Public Health 2009; 40:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/30\">",
"      Cartwright E, Rouphael N, Jain S, Ilksoy N. Pleural effusion in a patient with AIDS. Clin Infect Dis 2008; 46:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/31\">",
"      Cadranel JL, Chouaid C, Denis M, et al. Causes of pleural effusion in 75 HIV-infected patients. Chest 1993; 104:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/32\">",
"      Miller RF, Howling SJ, Reid AJ, Shaw PJ. Pleural effusions in patients with AIDS. Sex Transm Infect 2000; 76:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/33\">",
"      Katz AS, Niesenbaum L, Mass B. Pleural effusion as the initial manifestation of disseminated cryptococcosis in acquired immune deficiency syndrome. Diagnosis by pleural biopsy. Chest 1989; 96:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/34\">",
"      Grum EE, Schwab R, Margolis ML. Cryptococcal pleural effusion preceding cryptococcal meningitis in AIDS. Am J Med Sci 1991; 301:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/35\">",
"      Shankar EM, Kumarasamy N, Bella D, et al. Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS. Can Respir J 2006; 13:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/36\">",
"      Marshall BC, Cox JK Jr, Carroll KC, Morrison RE. Histoplasmosis as a cause of pleural effusion in the acquired immunodeficiency syndrome. Am J Med Sci 1990; 300:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/37\">",
"      Young EJ, Hirsh DD, Fainstein V, Williams TW. Pleural effusions due to Cryptococcus neoformans: a review of the literature and report of two cases with cryptococcal antigen determinations. Am Rev Respir Dis 1980; 121:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/38\">",
"      Yoshino Y, Kitazawa T, Tatsuno K, et al. Cryptococcal pleuritis containing a high level of adenosine deaminase in a patient with AIDS: a case report. Respiration 2010; 79:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/39\">",
"      Newman TG, Soni A, Acaron S, Huang CT. Pleural cryptococcosis in the acquired immune deficiency syndrome. Chest 1987; 91:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/40\">",
"      Paniago AM, de Freitas AC, Aguiar ES, et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil. J Infect 2005; 51:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/41\">",
"      Roy I, Mukhopadhyay C, Ayyagari A. Multisystem involvement of microfilaria in a HIV positive patient. Nepal Med Coll J 2004; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/42\">",
"      Wheat J, French ML, Kohler RB, et al. The diagnostic laboratory tests for histoplasmosis: analysis of experience in a large urban outbreak. Ann Intern Med 1982; 97:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/43\">",
"      Schnapp LM, Geaghan SM, Campagna A, et al. Toxoplasma gondii pneumonitis in patients infected with the human immunodeficiency virus. Arch Intern Med 1992; 152:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/44\">",
"      Chenoweth CE, Singal S, Pearson RD, et al. Acquired immunodeficiency syndrome-related visceral leishmaniasis presenting in a pleural effusion. Chest 1993; 103:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/45\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/46\">",
"      O'Brien RF, Cohn DL. Serosanguineous pleural effusions in AIDS-associated Kaposi's sarcoma. Chest 1989; 96:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/47\">",
"      Sivit CJ, Schwartz AM, Rockoff SD. Kaposi's sarcoma of the lung in AIDS: radiologic-pathologic analysis. AJR Am J Roentgenol 1987; 148:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/48\">",
"      Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/49\">",
"      Judson MA, Postic B. Chylothorax in a patient with AIDS and Kaposi's sarcoma. South Med J 1990; 83:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/50\">",
"      Fan W, Bubman D, Chadburn A, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 2005; 79:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/51\">",
"      Nobler MP. Pulmonary irradiation for Kaposi's sarcoma in AIDS. Am J Clin Oncol 1985; 8:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/52\">",
"      Maradona JA, Carton JA, Asensi V, Rodr&iacute;guez-Guardado A. AIDS-related Kaposi's sarcoma with chylothorax and pericardial involvement satisfactorily treated with liposomal doxorubicin. AIDS 2002; 16:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/53\">",
"      Godoy MC, Rouse H, Brown JA, et al. Imaging features of pulmonary Kaposi sarcoma-associated immune reconstitution syndrome. AJR Am J Roentgenol 2007; 189:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/54\">",
"      Guihot A, Couderc LJ, Agbalika F, et al. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study. Eur Respir J 2005; 26:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/55\">",
"      Batungwanayo J, Taelman H, Allen S, et al. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS 1993; 7:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/56\">",
"      Eisner MD, Kaplan LD, Herndier B, Stulbarg MS. The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma. Chest 1996; 110:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/57\">",
"      Sider L, Weiss AJ, Smith MD, et al. Varied appearance of AIDS-related lymphoma in the chest. Radiology 1989; 171:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/58\">",
"      Lee AM, Katner HP. AIDS-related lymphoma diagnosed by flow cytometry of a pleural effusion. South Med J 1991; 84:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/59\">",
"      Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997; 90:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/60\">",
"      Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/61\">",
"      Sider L, Horton ES. Pleural effusion as a presentation of AIDS-related lymphoma. Invest Radiol 1989; 24:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/62\">",
"      Green I, Espiritu E, Ladanyi M, et al. Primary lymphomatous effusions in AIDS: a morphological, immunophenotypic, and molecular study. Mod Pathol 1995; 8:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/63\">",
"      Aoki Y, Tosato G. Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas. Leuk Lymphoma 2001; 41:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/64\">",
"      Morassut S, Vaccher E, Balestreri L, et al. HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. Radiology 1997; 205:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/65\">",
"      Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007; 111:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/66\">",
"      Ascoli V, Mastroianni CM, Galati V, et al. Primary effusion lymphoma containing human herpesvirus 8 DNA in two AIDS patients with Kaposi's sarcoma. Haematologica 1998; 83:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/67\">",
"      Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007; 60:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23993/abstract/68\">",
"      Acierno LJ. Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review. J Am Coll Cardiol 1989; 13:1144.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6693 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23993=[""].join("\n");
var outline_f23_27_23993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTIOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pneumocystis jirovecii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nocardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cryptococcus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histoplasma capsulatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Toxoplasma gondii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MALIGNANT EFFUSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Multicentric Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER NONINFECTIOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6693|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/38/42593\" title=\"diagnostic image 1\">",
"      Hemorrhagic pleural effusion in Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6693|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/18/290\" title=\"picture 1A\">",
"      AIDS related KS skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/59/16305\" title=\"picture 1B\">",
"      KS yellow perilesional halo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/46/39648\" title=\"picture 1C\">",
"      KS plaque like lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/40/43656\" title=\"picture 2\">",
"      PEL staining",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/59/13245\" title=\"table 1A\">",
"      Pleural effusions in HIV I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/31/509\" title=\"table 1B\">",
"      Pleural effusions in HIV II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=related_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=related_link\">",
"      Cardiac involvement in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40756?source=related_link\">",
"      Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21161?source=related_link\">",
"      Clinical manifestations and diagnosis of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/20/42308?source=related_link\">",
"      Epidemiology and control of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=related_link\">",
"      Pulmonary involvement in AIDS-related Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43625?source=related_link\">",
"      Treatment of visceral leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22261?source=related_link\">",
"      Tuberculous pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_27_23994="Fetal growth restriction: Evaluation and management";
var content_f23_27_23994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal growth restriction: Evaluation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Robert Resnik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/27/23994/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/27/23994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing the constitutionally small fetus from the growth restricted fetus is a complex diagnostic and management problem, but is important. A constitutionally small fetus achieves its normal growth potential and has a good prognosis whereas the fetus whose growth potential is restricted is at increased risk of perinatal morbidity and mortality. Fetal growth restriction (FGR) that results from intrinsic fetal factors such as aneuploidy, congenital malformations, and fetal infection carries a guarded prognosis that often cannot be improved by any intervention. FGR related to uteroplacental insufficiency has a better prognosis, but is still associated with an increased risk of adverse outcome.",
"   </p>",
"   <p>",
"    The obstetrical provider's tasks are to identify when suboptimal growth occurs, determine its cause and severity, counsel the parents, consult with neonatal colleagues, closely monitor fetal growth and well-being, and select the appropriate time for and route of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of FGR is based upon sonographic estimation of fetal weight, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete history and physical examination is performed to look for maternal disorders associated with impaired fetal growth (eg, alcohol or tobacco use, maternal vascular disease). In addition, obstetrical imaging and laboratory evaluations are performed to look for fetal or placental etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fetal survey",
"      </strong>",
"      &mdash; A detailed fetal anatomic survey is recommended in all cases since major congenital anomalies are frequently associated with failure to maintain normal fetal growth. Among malformed infants, the frequency of FGR ranges from 20 to 60 percent, with the highest risk in infants with multiple anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/1\">",
"       1",
"      </a>",
"      ], while approximately 10 percent of FGR is accompanied by congenital anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/2\">",
"       2",
"      </a>",
"      ]. Some anomalies associated with FGR include omphalocele, diaphragmatic hernia, skeletal dysplasia, and some congenital heart defects; thus, a more formal examination of the fetal heart (fetal echocardiogram) is indicated if there is any question of cardiac abnormality on an expert (level II) ultrasound examination. Polyhydramnios is associated with trisomy 18 and several congenital anomalies. (See individual topic reviews on each subject).",
"     </li>",
"     <li>",
"      <strong>",
"       Karyotype",
"      </strong>",
"      &mdash; Fetal karyotyping is suggested when FGR is early onset and symmetric (second trimester), severe (&lt;3rd percentile), or accompanied by polyhydramnios (suggestive of trisomy 18) or structural anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/3\">",
"       3",
"      </a>",
"      ]. Ten to 40 percent of structurally abnormal, growth restricted fetuses will have an abnormal karyotype [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]; the highest risk is in those with multiple anomalies or certain types of anomaly. By comparison, only 2 percent of structurally normal, growth restricted fetuses have a chromosomal abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/4\">",
"       4",
"      </a>",
"      ]. Early onset FGR is commonly observed with trisomy 18, trisomy 13, and triploidy (",
"      <a class=\"graphic graphic_table graphicRef72782 \" href=\"UTD.htm?32/54/33643\">",
"       table 1",
"      </a>",
"      ). Ultrasound markers suggestive of aneuploidy include echogenic bowel, nuchal thickening, and abnormal hand positioning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"       \"Sonographic findings associated with fetal aneuploidy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Viral infection",
"      </strong>",
"      &mdash; When there is a clinical suspicion of viral infection (eg, maternal or fetal",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of cytomegalovirus, rubella, varicella), maternal serum should be examined for evidence of seroconversion. Specific amniotic fluid viral DNA testing can also be performed, when indicated. Sonographic markers for viral infection are often nonspecific, but include echogenicity and calcification of the brain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liver, and hydrops. (See individual topic reviews on viral infections during pregnancy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessment for congenital and acquired thrombophilic disorders is not recommended, as evidence for an association between the inherited thrombophilias and FGR is weak. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link&amp;anchor=H7898294#H7898294\">",
"     \"Inherited thrombophilias in pregnancy\", section on 'Fetal growth restriction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the fetus is small, but anatomically normal with an appropriate amniotic fluid volume and growth rate, the outcome will usually be a normal, constitutionally small neonate. It is imperative to distinguish between the constitutionally small fetus and the fetus with pathologic growth restriction so that appropriate interventions can be implemented to reduce adverse outcomes associated with pathologic growth restriction and avoid unnecessary interventions in the healthy small fetus. In this regard, it is important to recognize ethnic and geographic differences in growth potential. As an example, if one compares fetal growth curves derived from US national data to those from Japan and China, it is clear that the slopes of the curves are similar, but there are different weight cut-offs for the 10th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This had led to the development of \"customized\" growth curves, which take into account fetal growth potential based upon the mother's height, pre-pregnant weight, parity, and ethnicity, all strong contributors to ultimate fetal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This approach more reliably distinguishes those fetuses who are truly growth restricted and at increased risk of morbidity and mortality from those who are small but normal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of fetal growth restriction\", section on 'Customized growth curves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach is to identify the sonographic findings most consistently associated with adverse perinatal outcome. In a prospective multicenter observational study including 1116 consecutive fetuses with estimated fetal weight &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    centile, all 8 perinatal deaths occurred among the 826 fetuses with estimated fetal weight &lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile, and 6 of these fetuses had abnormal umbilical artery Doppler results (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Doppler velocimetry'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730312\">",
"    <span class=\"h2\">",
"     Antepartum fetal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to monitoring the fetus with suspected growth restriction has not been established; there is essentially no evidence from randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/12\">",
"     12",
"    </a>",
"    ]. Serial ultrasound evaluation of fetal growth, fetal behavior (BPP), and impedance to blood flow in fetal arterial and venous vessels (Doppler velocimetry) form the cornerstone of evaluation of the fetal condition and decision making. The purpose is to try to identify those fetuses who are at highest risk of in utero demise and neonatal morbidity, and thus may benefit from intervention by preterm delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Serial fetal weight assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal weight estimates are calculated using various published equations and formulae. The computed weight is then plotted on a population-based or customized growth curve, which allows the clinician to determine when the estimated weight is below the 10th percentile (",
"    <a class=\"graphic graphic_table graphicRef56847 \" href=\"UTD.htm?16/54/17261\">",
"     table 2",
"    </a>",
"    ) and to follow growth velocity. Serial sonograms are typically obtained at two- to four-week intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/3\">",
"     3",
"    </a>",
"    ]; persistent growth deficiency in multiple examinations over many weeks strengthens the likelihood of FGR. Conversely, normal growth velocity in a small fetus suggests a constitutionally small but normal fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/25?source=see_link\">",
"     \"Prenatal sonographic assessment of fetal weight\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of fetal growth restriction\", section on 'Customized growth curves'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Doppler velocimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler velocimetry of the umbilical artery is recommended as the primary surveillance tool for monitoring pregnancies in which FGR is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/13\">",
"     13",
"    </a>",
"    ]. It has been well established by numerous randomized trials that the use of this tool can significantly reduce perinatal death, as well as unnecessary induction of labor in the preterm growth restricted fetus. A Cochrane review of 18 studies comparing the use of Doppler to no Doppler in high risk pregnancies showed a reduction of perinatal deaths by 29 percent (OR 0.71, 95% CI 0.52-0.98; 1.2 versus 1.7 percent; number needed to treat 203), and significantly fewer labor inductions and cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler velocimetry is a good tool for fetal assessment in FGR when the etiology is placental dysfunction related to progressive obliteration of the villous vasculature. As placental dysfunction worsens, umbilical artery blood flow resistance increases and transfer of substrates, oxygen, and fetal waste products becomes increasingly impaired. Initially, fetal compensatory responses can be seen in the cerebral arterial circulation, but ultimately fetal cardiac decompensation can occur and is reflected by a fall in forward flow in the ductus venosus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6217313\">",
"    <span class=\"h4\">",
"     Umbilical artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in umbilical artery resistance leading to reduced end diastolic flow is consistently seen when 30 percent of the villous vasculature ceases to function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/15\">",
"     15",
"    </a>",
"    ]. Normal or reduced end diastolic flow is rarely associated with significant perinatal morbidity or mortality and is strong evidence of fetal well-being, thus provides support for delaying delivery when it is important to achieve further fetal maturity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/16\">",
"     16",
"    </a>",
"    ]. Absent or reversed end-diastolic flow in the umbilical artery occurs when 60 to 70 percent of the villous vasculature is obliterated and is evidence of poor fetal condition [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/15\">",
"     15",
"    </a>",
"    ]. These fetuses eventually show the metabolic and biophysical consequences of worsening hypoxia, including acidosis, loss of heart rate variability, and loss of fetal movement, breathing, and tone.",
"   </p>",
"   <p>",
"    As might be expected, reversed diastolic flow is associated with poorer neonatal outcomes than absent diastolic flow. For example, a study including 143 FGR pregnancies that compared",
"    <span class=\"nowrap\">",
"     neonatal/perinatal",
"    </span>",
"    mortality with reversed versus absent flow found mortality was over five-fold higher when reversed flow was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6217358\">",
"    <span class=\"h4\">",
"     Middle cerebral artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilation and high diastolic flow in the middle cerebral artery reflect compensatory cerebral vasodilatation (brain-sparing effect) secondary to fetal hypoxia and result in a reduced pulsatility index (MCA-PI), [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. These changes may occur one to three weeks before deterioration of fetal biophysical parameters, but the prognostic value is low.",
"    <br/>",
"    <br/>",
"    There have been several reports of normalization of the MCA-PI when fetal death was imminent, but it is not a consistent finding, thus its use in timing of delivery is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6217320\">",
"    <span class=\"h4\">",
"     Ductus venosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;With progressively increasing umbilical arterial resistance, fetal cardiac performance can become impaired and central venous pressure increases, resulting in reduced diastolic flow in the ductus venosus and other large veins. Vasodilatation of the ductus venosus further diverts nutrient and oxygen rich blood to the heart, but enhances retrograde transmission of atrial pressure. An absent or reversed ductus venous a-wave indicates cardiovascular instability and can be a sign of impending acidemia and death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Although overall sensitivity and specificity for fetal ph &lt;7.20 are only 65 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/22\">",
"     22",
"    </a>",
"    ], the duration of the absent or reversed ductus venous a-wave needs to be taken into account and appears to impact outcome independently of gestational age. Each day of this Doppler abnormality doubles the odds of stillbirth, and fetal survival for more than one week is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"     \"Venous Doppler for fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6220639\">",
"    <span class=\"h3\">",
"     Biophysical profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biophysical profile (BPP) is a useful method for monitoring the fetus because it provides an evaluation of multiple acute and chronic fetal physiologic parameters, is relatively easy to perform, and is a reliable test of fetal well-being (fetal death within one week of a normal test score is rare) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/24\">",
"     24",
"    </a>",
"    ]. Amniotic fluid assessment is a component of the BPP or modified BPP. Chronic placental insufficiency results in both FGR and oligohydramnios and observational studies have reported that pregnancies complicated by FGR and oligohydramnios have a modestly increased risk of perinatal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Conversely, normal amniotic fluid volume is infrequently associated with either FGR or fetal demise, unless the cause is a congenital malformation or aneuploidy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=see_link\">",
"     \"Oligohydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Application of the BPP to the growth restricted fetus remote from term may be less reliable since the preterm fetus may not have achieved maturity of the biophysiologic processes measured by this test. Furthermore, although many large observational studies have demonstrated the usefulness of the BPP in antepartum fetal assessment, there is a paucity of evidence derived from randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The BPP is typically obtained once or twice per week; however, more frequent testing, as often as daily, is indicated for fetuses at highest risk, including, but not limited to, severe FGR (less than the fifth percentile), severe oligohydramnios, absent or reversed umbilical artery flow on Doppler velocimetry, or equivocal BPP score (ie,",
"    <span class=\"nowrap\">",
"     6/10).",
"    </span>",
"    Very preterm, severely growth restricted fetuses can deteriorate rapidly; they should be monitored closely using multiple modalities if delivery is to be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/18,28\">",
"     18,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13307467\">",
"    <span class=\"h3\">",
"     Outpatient versus inpatient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with pregnancies complicated by FGR are usually evaluated and monitored as outpatients. There are no data on which to base indications for hospitalization. We and other experts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/29\">",
"     29",
"    </a>",
"    ] consider hospitalization for selected women who need daily or more frequent maternal or fetal assessment (eg, daily BPP because of reversed diastolic flow). Hospitalization provides more convenient access for daily fetal testing and allows prompt evaluation and intervention in the event of decreased fetal activity or other complications, but there is no evidence that hospitalization improves fetal growth or outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/30\">",
"     30",
"    </a>",
"    ]. Decisions about ambulatory versus in-hospital care should be made on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6217351\">",
"    <span class=\"h2\">",
"     Temporal sequence of fetal deterioration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The temporal sequence of Doppler changes in the peripheral and central circulatory systems of the growth restricted fetus is summarized below and in the figure (",
"    <a class=\"graphic graphic_figure graphicRef73075 \" href=\"UTD.htm?30/18/31022\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/18-20,31-33\">",
"     18-20,31-33",
"    </a>",
"    ]. However, progression through the entire sequence does not always occur before delivery; Doppler abnormalities in some growth restricted fetuses progress slowly or not at all. The sequence is most likely to progress when FGR and Doppler abnormalities are identified in the second trimester and the Doppler indices worsen within the first two weeks of monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease in umbilical venous volume flow occurs early and precedes clinical recognition of growth delay [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Umbilical venous blood flow is redistributed away from the fetal liver and towards the heart. Liver size decreases, causing a lag in fetal abdominal circumference, which is the first biometric sign of fetal growth restriction.",
"     </li>",
"     <li>",
"      The umbilical artery Doppler index increases (diminished end diastolic flow) due to increased resistance in placental vasculature.",
"     </li>",
"     <li>",
"      The middle cerebral artery Doppler index decreases (increased end diastolic flow), resulting in preferential perfusion of the brain (brain sparing effect).",
"     </li>",
"     <li>",
"      Increasing villous obliteration increases placental resistance, leading to absent and then reversed end diastolic flow in the umbilical artery.",
"     </li>",
"     <li>",
"      Myocardial dysfunction due to chronic hypoxia and nutritional deprivation, as well as increased fetoplacental arterial impedance, results in increased ductus venous indices. As cardiac performance deteriorates, absent or reversed end diastolic flow in the ductus venosus and pulsatile umbilical venous flow may develop, which can be preterminal events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At this point, biophysical changes usually become apparent: the nonstress test becomes nonreactive, the biophysical profile score falls, and late decelerations accompany contractions.",
"   </p>",
"   <p>",
"    However, the cardiovascular (Doppler) and behavioral (BPP) manifestations of fetal deterioration in FGR fetuses can occur largely independent of each other, resulting in discordant Doppler and BPP findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/36\">",
"     36",
"    </a>",
"    ]. The best approach when this occurs is not clear and the physician must analyze each case individually, taking into account such factors as the obstetrical situation, gestational age, degree of abnormality, and results from other tests of fetal well-being.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730474\">",
"    <span class=\"h2\">",
"     Frequency of fetal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of fetal surveillance is based upon the severity of findings and whether the examinations are being done to monitor fetal well-being, which requires relatively frequent assessment, or fetal growth, which is assessed over intervals of two to four weeks.",
"   </p>",
"   <p>",
"    The Society for Maternal-Fetal Medicine publications committee suggests umbilical artery Doppler studies every one to two weeks initially, and if normal, the interval can be decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/13\">",
"     13",
"    </a>",
"    ]. In general, when umbilical artery end diastolic flow is present and stable, we follow the fetus with weekly Doppler evaluation to determine the pattern of progression. The BPP is used either once weekly as an interval test between Doppler examinations or twice weekly, with one test at the time of the Doppler examination; there are no data to support one approach over the other. One trial reported that growth restricted fetuses with normal umbilical artery Doppler impedance could be safely evaluated (and with fewer interventions) with fortnightly, rather than twice weekly, surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/37\">",
"     37",
"    </a>",
"    ]. This approach would be cost effective without compromising clinical efficacy, but requires further corroboration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weekly Doppler should be complemented by twice weekly BPP or another combination of two antenatal tests (nonstress test and modified BPP or BPP) when FGR is complicated by oligohydramnios, preeclampsia, deceleration of fetal growth, increasing umbilical Dopper index, or other complications, even when umbilical artery end diastolic flow is present.",
"   </p>",
"   <p>",
"    Absent or reversed end diastolic flow in the umbilical artery is potentially a sign of impending fetal cardiovascular and metabolic deterioration. If either of these abnormal patterns is present and the fetus is not immediately delivered because of extreme prematurity, then",
"    <strong>",
"     daily",
"    </strong>",
"    BPP and Doppler are recommended. The absence of abnormal flow patterns in the ductus venosus may be used to support the decision to extend such a pregnancy, and may enable the pregnancy to be prolonged for as long as two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antenatal steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antenatal steroids for reducing neonatal morbidity and mortality in the preterm growth restricted neonate remains controversial, with two large studies showing conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Until more information is available, it is appropriate to administer a course of antenatal steroids in case preterm delivery occurs. Multiple series have found that both spontaneous and indicated preterm delivery are more common in growth restricted fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Ideally, one course of steroids is given between 24 and 34 weeks of gestation in the week before delivery is expected. Timing is based on the severity of FGR, Doppler findings, rate of progression, and presence of comorbid conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three studies observed that growth restricted fetuses with absent end diastolic flow often show transient improvement in blood flow after glucocorticoid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In fact, fetuses that did not show increased end diastolic flow appeared to have poorer neonatal outcomes. The reason sicker fetuses are unable to mount a vascular response to glucocorticoid administration is unclear. One action of glucocorticoids is to enhance the tropic effect of catecholamines on heart muscle. It is hypothesized that inotropy does not improve in sicker fetuses because they have impaired cardiac wall compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fetal blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, fetal blood sampling (FBS) was used in the assessment of fetal acid base status in severely growth restricted fetuses to assist in the identification of the optimal timing for delivery. However, FBS carries a 9 to 14 percent rate of procedure-related loss among growth restricted fetuses, thus its value for longitudinal assessment of fetal well-being is mitigated by the high risk of fetal death. Since FGR can be managed adequately without invasive techniques, FBS is not recommended to follow fetal status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence that any maternal antenatal treatment enhances fetal growth in growth restricted fetuses. Numerous approaches have been tried in small randomized trials, including nutritional supplementation, maternal oxygen therapy, and interventions to improve blood flow to the placenta, such as plasma volume expansion, low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , bed rest, and beta-mimetics, calcium channel blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/30,46-49\">",
"     30,46-49",
"    </a>",
"    ]. None have consistently been shown to be of value. In smokers, an intensive smoking cessation program might be of value, and has other pregnancy and health benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term, maternal hyperoxia may improve fetal acid base status at the time of delivery. Although its long-term use has been reported to lower perinatal mortality compared to controls, the differences may be due to more advanced gestational age in the oxygen-treated group [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/52\">",
"     52",
"    </a>",
"    ]. Antihypertensive therapy of hypertensive gravidas does not improve fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TIMING OF DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little consensus about the optimal timing of delivery of the high risk preterm growth restricted fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/56\">",
"     56",
"    </a>",
"    ]. The decision is determined by both gestational age and fetal condition. The body of information applicable to management and evaluation of these fetuses is complex and in evolution. Nevertheless, there is consensus that the growth restricted fetus should be delivered if the risk of fetal death, as determined by antepartum monitoring tests, exceeds the risk of neonatal death, which is highly dependent on gestational age.",
"   </p>",
"   <p>",
"    This assessment is difficult to make given the relatively poor predictive value of antenatal tests for fetal surveillance and the wide variation in neonatal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    rates remote from term. A few trials have attempted to answer the question of when to intervene in these pregnancies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Growth Restriction Intervention Trial (GRIT) randomly assigned pregnant women between 24 and 36 weeks with FGR to immediate (n = 296) or delayed (n = 291) delivery if their obstetrician was uncertain about when to intervene [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/56\">",
"       56",
"      </a>",
"      ]. Forty percent of these pregnancies had absent or reversed end diastolic umbilical artery flow. In the delayed delivery group, delivery occurred when the obstetrician was no longer uncertain about intervening, which took a median 4.9 days.",
"      <br/>",
"      <br/>",
"      The immediate delivery group had fewer stillbirths (2 versus 9 with delayed delivery), but more neonatal and infant deaths (27 versus 18), especially when randomization occurred before 31 weeks. Follow-up data up to age 13 years showed no differences between groups in cognition, language, motor, or parent-assessed behavior scores on standardized tests; follow-up was achieved in approximately 70 percent of survivors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. Cognition scores were close to the standardized normal range.",
"      <br/>",
"      <br/>",
"      These data suggest that delaying delivery of the very preterm growth restricted fetus in the setting of uncertainty results in some stillbirths, but immediate delivery produces an almost equal number of neonatal deaths, and neither approach results in better long-term neurodevelopmental outcome. Although widely cited, these studies are difficult to evaluate due to the lack of standard criteria for intervention.",
"     </li>",
"     <li>",
"      A prospective multicenter study came to similar conclusions. Over 600 singleton fetuses at less than 33 weeks of gestation with normal anatomy and karyotype, FGR, intact membranes, and elevated umbilical artery resistance were followed with serial examinations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/59\">",
"       59",
"      </a>",
"      ]. At very preterm gestations, gestational age was the most important factor predicting outcome: neonatal survival was less than 50 percent before 26 weeks of gestation; intact survival was less than 50 percent before 28 weeks of gestation.",
"      <br/>",
"      <br/>",
"      After 26 to 28 weeks, fetal assessment tests (ductus venous Doppler, biophysical profile) were useful in deciding whether to continue expectant management to allow further growth and maturation versus intervention to prevent in utero demise. A birth weight over 600 g was also an important predictor of survival.",
"     </li>",
"     <li>",
"      The DIGITAT (Disproportionate Intrauterine Growth Intervention Trial At Term) trial randomly assigned 650 pregnant women over 36.0 weeks of gestation with suspected FGR to induction of labor or expectant monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. The primary outcome was a composite measure of adverse neonatal outcome (death before hospital discharge, five-minute Apgar score &lt;7, umbilical artery pH &lt;7.05, or admission to the intensive care unit) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/60\">",
"       60",
"      </a>",
"      ]. Neonatal morbidity was analyzed separately using Morbidity Assessment Index for Newborns (MAIN) score [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The induction group delivered 10 days earlier and weighed 130 g less (mean difference &minus;130 g, 95% CI &minus;188 g to &minus;71 g) than the expectantly managed group, but had statistically similar composite adverse outcome (6.1 versus 5.3 percent with expectant management) and cesarean delivery rates (about 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/60\">",
"       60",
"      </a>",
"      ]. MAIN scores were also similar for both groups; the only significant difference was a higher proportion of hyperbilirubinemia in the induction group (10.4 versus 5.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/61\">",
"       61",
"      </a>",
"      ]. In addition, developmental and behavioral outcomes at 2 years of age were similar for both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/62\">",
"       62",
"      </a>",
"      ]. The authors concluded that both approaches were reasonable, and the choice should depend on patient preference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6217432\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the data presented above, data from retrospective studies, expert opinion, and clinical experience, we have developed the following approach to evaluation and management of FGR (",
"    <a class=\"graphic graphic_table graphicRef68553 \" href=\"UTD.htm?8/61/9180\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Remote from term",
"    </span>",
"    &nbsp;&mdash;&nbsp;In growth restricted fetuses remote from term (&lt;34 weeks of gestation), evidence of normal umbilical artery flow by Doppler velocimetry is reassuring with regard to immediate fetal outcome; prolongation of pregnancy to gain further fetal maturity is reasonable in these cases. Between 26 and 29 weeks of gestation, each day in utero has been estimated to improve survival by 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/59\">",
"     59",
"    </a>",
"    ]. Morbidity and mortality remain relatively high under 32 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/63\">",
"     63",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    On the other hand, absence and particularly reversal of flow are ominous findings; the high risk of fetal demise with expectant management in these cases can exceed the risks associated with preterm delivery. We would immediately deliver any pregnancy &ge;32 weeks with reversed flow and &ge;34 weeks with absent flow, but would try to delay delivery in those under 32 weeks with reversed flow and those under 34 weeks with absent flow. The timing of delivery in these cases depends upon the etiology and severity of the FGR (&lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    versus &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile), the results of antenatal fetal testing, and the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of additional risk factors for an adverse outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Changes in the venous circulation, including evidence of flow reversals in the ductus venosus or pulsatile umbilical venous flow, generally occur later than those observed in the arterial circulation. They appear to be more predictive of impending adverse outcome, and thus generally warrant immediate delivery regardless of gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Although the use of venous Doppler interrogation remains largely investigational, a growing number of maternal-fetal medicine specialists are using the information gained from such studies to avoid very preterm delivery in fetuses with absent or reversed end-diastolic arterial flow and reassuring antepartum fetal testing (NST, BPP). In these pregnancies, the absence of abnormal flow patterns in the ductus venosus may be used to support the decision to extend the pregnancy to 32 to 34 weeks, if other tests of fetal well-being remain reassuring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=see_link\">",
"     \"Venous Doppler for fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These recommendations are similar to those of the Society for Maternal-Fetal Medicine publications committee, which suggests expectant management until 34 weeks of gestation for suspected FGR with absent end-diastolic umbilical artery flow as long as fetal surveillance remains reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/13\">",
"     13",
"    </a>",
"    ]. For FGR with reversed end-diastolic umbilical artery flow and reassuring fetal surveillance, they suggest delivery at 32 weeks of gestation. When end-diastolic umbilical artery flow is decreased (but not absent or reversed) with reassuring fetal surveillance, delivery may be delayed until &gt;37 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Late preterm and term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of the late preterm (34 to",
"    <span class=\"nowrap\">",
"     36",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks) or early term",
"    <span class=\"nowrap\">",
"     (37",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks) growth restricted fetus is recommended if there are additional risk factors for adverse outcome, such as maternal",
"    <span class=\"nowrap\">",
"     medical/obstetrical",
"    </span>",
"    disorders, arrest of growth over a three- to four-week interval,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absence or reversal of Doppler flow in the umbilical artery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/66\">",
"     66",
"    </a>",
"    ]. At this gestational age range, the risks of preterm birth are relatively low, and thus outweighed by the risks estimated to be associated with these variables. However, the patient&rsquo;s specific clinical situation must be assessed and management individualized.",
"   </p>",
"   <p>",
"    For pregnancies with mild growth restriction at 34 to 37 weeks, normal umbilical artery Doppler flow, and no additional",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risk factors, delivery can be delayed until 38 to",
"    <span class=\"nowrap\">",
"     39",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks, when pulmonary maturity is likely [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Delivery at 37 to 38 weeks is reasonable if umbilical artery flow is decreased.",
"   </p>",
"   <p>",
"    Term pregnancies with FGR should be delivered and should not extend beyond 40 weeks of gestation. The risk of intrauterine fetal demise significantly increases at term, particularly as the severity of FGR increases. As an example, in a retrospective cohort study, the risk of intrauterine fetal death at 39 weeks was estimated as 32 per 10,000 ongoing pregnancies for fetal weight &lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile, 23 per 10,000 ongoing pregnancies for fetal weight &lt;5",
"    <sup>",
"     th",
"    </sup>",
"    percentile, 13 per 10,000 ongoing pregnancies for fetal weight &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile, and 2 per 10,000 ongoing pregnancies for fetal weight &ge;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTRAPARTUM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth restricted fetuses may exist in a state of mild-to-moderate chronic oxygen and substrate deprivation. Potential consequences include antepartum or intrapartum fetal heart rate abnormalities, passage of meconium with risk of aspiration, and neonatal polycythemia, impaired thermoregulation, hypoglycemia, and other metabolic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link&amp;anchor=H21#H21\">",
"     \"Small for gestational age infant\", section on 'Outcomes'",
"    </a>",
"    .) Consequently, it is imperative to optimize the timing of delivery (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Timing of delivery'",
"    </a>",
"    above), perform continuous intrapartum fetal monitoring to detect nonreassuring fetal heart rate patterns suggestive of progressive hypoxia during labor, and provide immediate skilled neonatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/71\">",
"     71",
"    </a>",
"    ]. Umbilical cord blood analysis should be considered as a component of establishing baseline neonatal status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link&amp;anchor=H2#H2\">",
"     \"Umbilical cord blood acid-base analysis\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of fetal heart rate abnormalities related to hypoxia is highest among fetuses with abnormal Doppler velocimetry. In one large series, no fetus with normal Doppler velocimetry was delivered with metabolic acidemia associated with chronic hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/72\">",
"     72",
"    </a>",
"    ]. Compared to growth restricted fetuses with normal umbilical artery Doppler ratios, growth restricted fetuses with a",
"    <span class=\"nowrap\">",
"     systolic/diastolic",
"    </span>",
"    ratio &gt;90",
"    <sup>",
"     th",
"    </sup>",
"    percentile for gestational age had significantly lower umbilical artery and vein pH values at birth (artery 7.23",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.08 versus 7.25",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.1; vein, 7.31",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.01 versus 7.34",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.09), an increased likelihood of nonreassuring fetal heart rate patterns (26 versus 9 percent), more admissions to the neonatal intensive care unit (41 versus 31 percent), and a higher incidence of respiratory distress (66 versus 27 percent).",
"   </p>",
"   <p>",
"    In the presence of reassuring antenatal testing, spontaneous or induced labor with continuous intrapartum monitoring is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. However, the frequency of cesarean delivery for nonreassuring fetal heart rate tracing is increased, given the increased prevalence of chronic hypoxia and oligohydramnios among these fetuses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the fetus is small for gestational age (SGA), but anatomically normal with an appropriate amniotic fluid volume and growth rate, the outcome will usually be a normal, constitutionally small neonate. By comparison, truly impaired fetal growth is associated with increased perinatal mortality and morbidity, and can have long-term effects on growth, development, and cardiovascular health. Morbidity and mortality in these cases is influenced by the etiology of FGR, early gestational age at onset of growth delay and preterm delivery, and severity of growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal, neonatal, and perinatal mortality are increased in SGA compared to appropriate for gestational age (AGA) infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/75-80\">",
"     75-80",
"    </a>",
"    ]. Both the severity of growth restriction and degree of prematurity contribute to the increased risk of neonatal death. Mortality and morbidity rise abruptly when birth weight is &le;5",
"    <sup>",
"     th",
"    </sup>",
"    percentile (",
"    <a class=\"graphic graphic_figure graphicRef56263 \" href=\"UTD.htm?13/6/13422\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/81\">",
"     81",
"    </a>",
"    ]. Congenital malformations, perinatal asphyxia, and transitional cardiorespiratory disorders contribute to the high mortality rate in term SGA infants, whereas complications of prematurity play a significant role as gestational age decreases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although neonatal mortality is higher in SGA than in AGA infants at every gestational age, neonatal mortality is similar for SGA and AGA infants at any given birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;SGA infants are at increased risk of neonatal morbidity compared to AGA infants, particularly when very premature and preterm births are more common in pregnancies complicated by FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. Short-term morbidities are related to both low birth weight and prematurity and include impaired thermoregulation, hypoglycemia,",
"    <span class=\"nowrap\">",
"     polycythemia/hyperviscosity,",
"    </span>",
"    hypocalcemia, hyperbilirubinemia, infection, and impaired immune function. Increased risks of acidemia, apnea, respiratory distress, intraventricular hemorrhage, and necrotizing enterocolitis have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/82,86\">",
"     82,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A broad range of adverse long-term outcomes has been reported, including small decreases in IQ (which are statistically, but not clinically, significant), a reduction in scores for executive cognitive functions (reflectiveness, visual memory and visual motor coordination, planning and sequential processing), and a sharply increased risk of cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/87-93\">",
"     87-93",
"    </a>",
"    ]. One report suggested that FGR has a negative impact on intellectual outcome even in the presence of catch-up growth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/94\">",
"     94",
"    </a>",
"    ]. As might be anticipated, the worst outcomes have been observed in the more severely growth-restricted infants who are preterm, and who exhibit the most overt evidence of impaired umbilical blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. Term FGR infants are also at risk of neurodevelopmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/98\">",
"     98",
"    </a>",
"    ]. There is some evidence that abnormal fetal middle cerebral artery Doppler flow associated with FGR is predictive of neurobehavioral impairment in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an interesting study comparing outcomes in growth restricted versus normally grown monozygotic twin pairs, the smaller cotwin had a lower verbal but not performance IQ score [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/101\">",
"     101",
"    </a>",
"    ]. These findings are unique since the study population naturally controls for parental IQ and education and other confounding variables such as gender and genetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link&amp;anchor=H21#H21\">",
"     \"Small for gestational age infant\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis for intact neurologic function is presumably more favorable for the growth restricted fetus when the cause is related to substrate deprivation, since catch up growth is possible; when the timing of delivery reflects the point when fetal risk exceeds neonatal risk; when the fetus remains well compensated antepartum and intrapartum; and when the infant receives appropriate neonatal care.",
"   </p>",
"   <p>",
"    There may also be deleterious effects of in utero growth restriction on subsequent adult health. The Barker hypothesis proposed that the endocrine-metabolic reprogramming that enabled the growth restricted fetus to compensate for the hostile intrauterine environment might lead to a metabolic syndrome in later life with development of hypertension, hypercholesterolemia, impaired glucose tolerance, and ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. A systematic review of 80 studies found that blood pressure rose 2 mmHg with each kilogram of decreasing birth weight and small head circumference was most consistently associated with high blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/104\">",
"     104",
"    </a>",
"    ]. Other studies have reported that FGR is associated with an increased risk of ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/103\">",
"     103",
"    </a>",
"    ], low normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/105\">",
"     105",
"    </a>",
"    ], and type 2 diabetes in adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/106\">",
"     106",
"    </a>",
"    ]. A study comparing cardiac function in 80 children who were growth restricted (mean age 5 years) and 120 controls found that the growth restricted children had a different cardiac shape, more globular ventricles, decreased stroke volume, and increased heart rate, as well as higher blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=see_link\">",
"     \"Possible role of low birth weight in the pathogenesis of essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a tendency to repeat SGA deliveries in successive pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Data derived from over 30,000 Norwegian births to women who delivered their first three children within a 10-year period showed that the risk of a SGA birth in a second pregnancy in women whose first delivery was 'not SGA' versus 'SGA' were 9 and 29 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/108\">",
"     108",
"    </a>",
"    ]. After two consecutive SGA births, the risk of a third was 44 percent.",
"   </p>",
"   <p>",
"    Furthermore, uteroplacental insufficiency may manifest in different ways in different pregnancies. Growth restriction, preterm delivery, preeclampsia, abruption, and stillbirth can all be sequelae of impaired placental function. The association between the birth of a SGA infant in a first pregnancy and stillbirth in a subsequent pregnancy was illustrated by analysis of data from the Swedish Birth Register (",
"    <a class=\"graphic graphic_table graphicRef56032 \" href=\"UTD.htm?18/19/18747\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/110\">",
"     110",
"    </a>",
"    ]; subsequent studies from the United States and Australia reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. The highest risk of stillbirth was in women who delivered a preterm SGA infant. Another series suggested a sibling delivered after the birth of a SGA infant (even if mildly SGA) was at increased risk of sudden infant death syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SUBSEQUENT PREGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In subsequent pregnancies, we address any potentially treatable causes of FGR (eg, cessation of smoking and alcohol intake, chemoprophylaxis and mosquito avoidance in areas where malaria is prevalent, balanced",
"    <span class=\"nowrap\">",
"     energy/protein",
"    </span>",
"    supplementation in women with significant nutritional deficiencies). (See individual topic reviews). Avoiding a short or long interpregnancy interval may also be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=see_link\">",
"     \"Interpregnancy interval and pregnancy outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some randomized trials reported that low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    prophylaxis during pregnancy reduced the risk of recurrent FGR in women at high-risk (eg, fetal growth restriction in a previous pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/114,115\">",
"     114,115",
"    </a>",
"    ], larger randomized trials did not confirm significant risk reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/116\">",
"     116",
"    </a>",
"    ]. Aspirin may be effective when FGR is related to preeclampsia. In a systematic review of 36 randomized trials including 23,638 women at high risk of developing preeclampsia, use of antiplatelet agents compared to placebo was associated with a 17 percent reduction in the risk of preeclampsia and a 10 percent reduction in the risk of SGA births (RR 0.90, 95% CI 0.83-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/117\">",
"     117",
"    </a>",
"    ]. Further study is needed.",
"   </p>",
"   <p>",
"    Antihypertensive therapy of hypertensive women, long-chain polyunsaturated fatty acid supplements, beta-mimetics, and bedrest do not prevent FGR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/27/23994/abstract/30,53-55,118,119\">",
"     30,53-55,118,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accurate dating by early ultrasonography is important to establish gestational age and intermittent ultrasound examinations are used to monitor fetal growth. Otherwise, prenatal management is routine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A detailed fetal anatomic survey is recommended in all cases of fetal growth restriction since major congenital anomalies are frequently associated with failure to maintain normal fetal growth.",
"     </li>",
"     <li>",
"      Fetal karyotyping is suggested if there are structural anomalies, early or severe symmetrical (&lt;3",
"      <sup>",
"       rd",
"      </sup>",
"      percentile) growth restriction, or polyhydramnios (suggestive of trisomy 18) since each of these findings is associated with an increased frequency of karyotypic abnormality.",
"     </li>",
"     <li>",
"      Maternal serum should be examined for evidence of seroconversion if there are maternal or fetal signs suggestive of viral infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antepartum management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serial ultrasound evaluation of fetal growth, fetal behavior (FPP), amniotic fluid volume, and impedance to blood flow in fetal arterial and venous vessels form the cornerstone of evaluation of the fetal condition and decision making. The frequency is based upon the severity of findings and whether the examinations are being done to monitor fetal well-being (one to seven times per week) or fetal growth (every two to four weeks). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Obstetrical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler velocimetry of the umbilical artery is recommended for monitoring pregnancies in which growth restriction is diagnosed because delivery prompted by abnormal Doppler ultrasonography reduces the frequency of perinatal death. Normal Doppler findings are reassuring and thus potentially allow prolongation of pregnancy and reduction in the number of unnecessary preterm inductions. Doppler assessment of the venous circulation may provide additional information for decision making in the very preterm fetus. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Doppler velocimetry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A course of antenatal glucocorticoids is recommended for preterm gestations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing of delivery is determined by both gestational age and fetal condition:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Remote from term, evidence of normal umbilical artery flow by Doppler velocimetry is reassuring with regard to immediate fetal outcome so continued fetal monitoring is reasonable to achieve further fetal maturity. We would immediately deliver any pregnancy &ge;32 weeks with reversed flow, but would try to delay delivery in those under 32 weeks with reversed flow and those under 34 weeks with absent flow. The timing of delivery in these cases depends upon the etiology and severity of the fetal growth restriction, the results of antenatal fetal testing, and the",
"      <span class=\"nowrap\">",
"       presence/absence",
"      </span>",
"      of additional risk factors for an adverse outcome. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term or late preterm growth restricted fetus is delivered if there is evidence of maternal hypertension, failure of apparent growth over a two- to four-week interval, the biophysical profile score is low (less than 6),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      umbilical arterial Doppler velocimetry reveals absence or reversal of flow. However, the specific clinical situation in each case must be considered and management individualized.",
"     </li>",
"     <li>",
"      When growth restriction is mild and uncomplicated (no fetal abnormalities or contributing maternal disorders), end diastolic flow is present, and antepartum fetal testing results are reassuring, delivery can be delayed until at least 37 weeks when pulmonary maturity is likely. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Late preterm and term'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Labor and vaginal delivery is a reasonable approach in the presence of normal antenatal testing. During labor, continuous intrapartum fetal monitoring is recommended to look for nonreassuring fetal heart rate patterns suggestive of progressive hypoxia during labor. The clinician should be prepared for rapid intervention if there is any evidence of fetal intolerance to labor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a tendency to repeat small for gestational age or low birth weight deliveries in successive pregnancies. Growth restriction, preterm delivery, preeclampsia, abruption, and stillbirth can all be sequelae of impaired placental function that may manifest in different ways in different pregnancies. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Recurrence risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/1\">",
"      Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988; 82:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/2\">",
"      Mendez H. Introduction to the study of pre- and postnatal growth in humans: a review. Am J Med Genet 1985; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Intrauterine growth restriction. ACOG Practice Bulletin #12. January 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/4\">",
"      Snijders RJ, Sherrod C, Gosden CM, Nicolaides KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. Am J Obstet Gynecol 1993; 168:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/5\">",
"      Zhang J, Bowes WA Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstet Gynecol 1995; 86:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/6\">",
"      Shinozuka, N, Masda, H, Taketani, Y. Standard Values of Fetal Ultrasonographic Biomtery. Japanese Journal of Medical Ultrasonics 1996; 12:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/7\">",
"      Fok TF, Lam TK, Lee N, et al. A prospective study on the intrauterine growth of Hong Kong Chinese babies. Biol Neonate 1987; 51:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/8\">",
"      Gardosi J. New definition of small for gestational age based on fetal growth potential. Horm Res 2006; 65 Suppl 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/9\">",
"      Gardosi J, Figueras F, Clausson B, Francis A. The customised growth potential: an international research tool to study the epidemiology of fetal growth. Paediatr Perinat Epidemiol 2011; 25:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/10\">",
"      Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol 2011; 204:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/11\">",
"      Unterscheider J, Daly S, Geary MP, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol 2013; 208:290.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/12\">",
"      Grivell RM, Wong L, Bhatia V. Regimens of fetal surveillance for impaired fetal growth. Cochrane Database Syst Rev 2012; :CD007113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/13\">",
"      Society for Maternal-Fetal Medicine Publications Committee, Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Am J Obstet Gynecol 2012; 206:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/14\">",
"      Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev 2010; :CD007529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/15\">",
"      Baschat AA. Fetal growth restriction - from observation to intervention. J Perinat Med 2010; 38:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/16\">",
"      Ott WJ. Intrauterine growth restriction and Doppler ultrasonography. J Ultrasound Med 2000; 19:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/17\">",
"      Vasconcelos RP, Brazil Frota Arag&atilde;o JR, Costa Carvalho FH, et al. Differences in neonatal outcome in fetuses with absent versus reverse end-diastolic flow in umbilical artery Doppler. Fetal Diagn Ther 2010; 28:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/18\">",
"      Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001; 18:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/19\">",
"      Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol 2002; 19:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/20\">",
"      Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001; 18:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/21\">",
"      Fieni S, Gramellini D, Piantelli G. Lack of normalization of middle cerebral artery flow velocity prior to fetal death before the 30th week of gestation: a report of three cases. Ultrasound Obstet Gynecol 2004; 24:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/22\">",
"      Baschat AA, Gembruch U, Weiner CP, Harman CR. Qualitative venous Doppler waveform analysis improves prediction of critical perinatal outcomes in premature growth-restricted fetuses. Ultrasound Obstet Gynecol 2003; 22:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/23\">",
"      Turan OM, Turan S, Berg C, et al. Duration of persistent abnormal ductus venosus flow and its impact on perinatal outcome in fetal growth restriction. Ultrasound Obstet Gynecol 2011; 38:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/24\">",
"      Dayal AK, Manning FA, Berck DJ, et al. Fetal death after normal biophysical profile score: An eighteen-year experience. Am J Obstet Gynecol 1999; 181:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/25\">",
"      Scifres CM, Stamilio D, Macones GA, Odibo AO. Predicting perinatal mortality in preterm intrauterine growth restriction. Am J Perinatol 2009; 26:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/26\">",
"      Chauhan SP, Taylor M, Shields D, et al. Intrauterine growth restriction and oligohydramnios among high-risk patients. Am J Perinatol 2007; 24:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/27\">",
"      Alfirevic Z, Neilson JP. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2000; :CD000038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/28\">",
"      Kaur S, Picconi JL, Chadha R, et al. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh &lt;1000 g. Am J Obstet Gynecol 2008; 199:264.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/29\">",
"      Lausman A, McCarthy FP, Walker M, Kingdom J. Screening, diagnosis, and management of intrauterine growth restriction. J Obstet Gynaecol Can 2012; 34:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/30\">",
"      G&uuml;lmezoglu AM, Hofmeyr GJ. Bed rest in hospital for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/31\">",
"      Cosmi E, Ambrosini G, D'Antona D, et al. Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. Obstet Gynecol 2005; 106:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/32\">",
"      Baschat AA. Venous Doppler evaluation of the growth-restricted fetus. Clin Perinatol 2011; 38:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/33\">",
"      Baschat AA. Ductus venosus Doppler for fetal surveillance in high-risk pregnancies. Clin Obstet Gynecol 2010; 53:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/34\">",
"      Turan OM, Turan S, Gungor S, et al. Progression of Doppler abnormalities in intrauterine growth restriction. Ultrasound Obstet Gynecol 2008; 32:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/35\">",
"      Rigano S, Bozzo M, Ferrazzi E, et al. Early and persistent reduction in umbilical vein blood flow in the growth-restricted fetus: a longitudinal study. Am J Obstet Gynecol 2001; 185:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/36\">",
"      Baschat AA, Galan HL, Bhide A, et al. Doppler and biophysical assessment in growth restricted fetuses: distribution of test results. Ultrasound Obstet Gynecol 2006; 27:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/37\">",
"      McCowan LM, Harding JE, Roberts AB, et al. A pilot randomized controlled trial of two regimens of fetal surveillance for small-for-gestational-age fetuses with normal results of umbilical artery doppler velocimetry. Am J Obstet Gynecol 2000; 182:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/38\">",
"      Elimian A, Verma U, Canterino J, et al. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol 1999; 93:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/39\">",
"      Schaap AH, Wolf H, Bruinse HW, et al. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 2001; 97:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/40\">",
"      Gardosi JO. Prematurity and fetal growth restriction. Early Hum Dev 2005; 81:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/41\">",
"      Bukowski R, Gahn D, Denning J, Saade G. Impairment of growth in fetuses destined to deliver preterm. Am J Obstet Gynecol 2001; 185:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/42\">",
"      Doubilet PM, Benson CB, Wilkins-Haug L, Ringer S. Fetuses subsequently born premature are smaller than gestational age-matched fetuses not born premature. J Ultrasound Med 2003; 22:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/43\">",
"      Robertson MC, Murila F, Tong S, et al. Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. Obstet Gynecol 2009; 113:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/44\">",
"      Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/45\">",
"      Nozaki AM, Francisco RP, Fonseca ES, et al. Fetal hemodynamic changes following maternal betamethasone administration in pregnancies with fetal growth restriction and absent end-diastolic flow in the umbilical artery. Acta Obstet Gynecol Scand 2009; 88:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/46\">",
"      G&uuml;lmezoglu AM, Hofmeyr GJ. Plasma volume expansion for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/47\">",
"      G&uuml;lmezoglu AM, Hofmeyr GJ. Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/48\">",
"      Newnham JP, Godfrey M, Walters BJ, et al. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. Aust N Z J Obstet Gynaecol 1995; 35:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/49\">",
"      von Dadelszen P, Dwinnell S, Magee LA, et al. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011; 118:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/50\">",
"      Figueras F, Meler E, Eixarch E, et al. Association of smoking during pregnancy and fetal growth restriction: subgroups of higher susceptibility. Eur J Obstet Gynecol Reprod Biol 2008; 138:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/51\">",
"      Aagaard-Tillery KM, Porter TF, Lane RH, et al. In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth. Am J Obstet Gynecol 2008; 198:66.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/52\">",
"      G&uuml;lmezoglu AM, Hofmeyr GJ. Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/53\">",
"      Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/54\">",
"      Redman CW. Controlled trials of antihypertensive drugs in pregnancy. Am J Kidney Dis 1991; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/55\">",
"      Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2001; :CD002252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/56\">",
"      When do obstetricians recommend delivery for a high-risk preterm growth-retarded fetus? The GRIT Study Group. Growth Restriction Intervention Trial. Eur J Obstet Gynecol Reprod Biol 1996; 67:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/57\">",
"      Thornton JG, Hornbuckle J, Vail A, et al. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet 2004; 364:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/58\">",
"      Walker DM, Marlow N, Upstone L, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol 2011; 204:34.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/59\">",
"      Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007; 109:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/60\">",
"      Boers KE, Vijgen SM, Bijlenga D, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ 2010; 341:c7087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/61\">",
"      Boers KE, van Wyk L, van der Post JA, et al. Neonatal morbidity after induction vs expectant monitoring in intrauterine growth restriction at term: a subanalysis of the DIGITAT RCT. Am J Obstet Gynecol 2012; 206:344.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/62\">",
"      van Wyk L, Boers KE, van der Post JA, et al. Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial. Am J Obstet Gynecol 2012; 206:406.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/63\">",
"      Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196:147.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/64\">",
"      Baschat AA. Doppler application in the delivery timing of the preterm growth-restricted fetus: another step in the right direction. Ultrasound Obstet Gynecol 2004; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/65\">",
"      Bilardo CM, Wolf H, Stigter RH, et al. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol 2004; 23:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/66\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. The investigation and management of the small-for gestational age fetus. Guideline 31, Novemeber 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/68\">",
"      Vergani P, Roncaglia N, Ghidini A, et al. Can adverse neonatal outcome be predicted in late preterm or term fetal growth restriction? Ultrasound Obstet Gynecol 2010; 36:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/69\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/70\">",
"      Pilliod RA, Cheng YW, Snowden JM, et al. The risk of intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet Gynecol 2012; 207:318.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/71\">",
"      Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/72\">",
"      Baschat AA, Weiner CP. Umbilical artery doppler screening for detection of the small fetus in need of antepartum surveillance. Am J Obstet Gynecol 2000; 182:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/73\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/74\">",
"      Werner EF, Savitz DA, Janevic TM, et al. Mode of delivery and neonatal outcomes in preterm, small-for-gestational-age newborns. Obstet Gynecol 2012; 120:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/75\">",
"      Battin MR, McCowan LM, George-Haddad M, Thompson JM. Fetal growth restriction and other factors associated with neonatal death in New Zealand. Aust N Z J Obstet Gynaecol 2007; 47:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/76\">",
"      Williams RL, Creasy RK, Cunningham GC, et al. Fetal growth and perinatal viability in California. Obstet Gynecol 1982; 59:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/77\">",
"      Wennergren M, Wennergren G, Vilbergsson G. Obstetric characteristics and neonatal performance in a four-year small for gestational age population. Obstet Gynecol 1988; 72:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/78\">",
"      Piper JM, Xenakis EM, McFarland M, et al. Do growth-retarded premature infants have different rates of perinatal morbidity and mortality than appropriately grown premature infants? Obstet Gynecol 1996; 87:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/79\">",
"      Kok JH, den Ouden AL, Verloove-Vanhorick SP, Brand R. Outcome of very preterm small for gestational age infants: the first nine years of life. Br J Obstet Gynaecol 1998; 105:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/80\">",
"      Gardosi J, Madurasinghe V, Williams M, et al. Maternal and fetal risk factors for stillbirth: population based study. BMJ 2013; 346:f108.",
"     </a>",
"    </li>",
"    <li>",
"     Manning, FA. Intrauterine growth retardation. In: Manning, FA, ed. Fetal medicine: Principles and practice. Appleton and Lange, Norwalk, CT 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/82\">",
"      Bernstein IM, Horbar JD, Badger GJ, et al. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol 2000; 182:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/83\">",
"      Simchen MJ, Beiner ME, Strauss-Liviathan N, et al. Neonatal outcome in growth-restricted versus appropriately grown preterm infants. Am J Perinatol 2000; 17:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/84\">",
"      Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol 2004; 191:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/85\">",
"      Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth restriction. Am J Obstet Gynecol 2003; 188:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/86\">",
"      Lackman F, Capewell V, Richardson B, et al. The risks of spontaneous preterm delivery and perinatal mortality in relation to size at birth according to fetal versus neonatal growth standards. Am J Obstet Gynecol 2001; 184:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/87\">",
"      Paz I, Laor A, Gale R, et al. Term infants with fetal growth restriction are not at increased risk for low intelligence scores at age 17 years. J Pediatr 2001; 138:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/88\">",
"      Tideman E, Mars&aacute;l K, Ley D. Cognitive function in young adults following intrauterine growth restriction with abnormal fetal aortic blood flow. Ultrasound Obstet Gynecol 2007; 29:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/89\">",
"      Blair E, Stanley F. Intrauterine growth and spastic cerebral palsy. I. Association with birth weight for gestational age. Am J Obstet Gynecol 1990; 162:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/90\">",
"      Jarvis S, Glinianaia SV, Torrioli MG, et al. Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet 2003; 362:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/91\">",
"      Geva R, Eshel R, Leitner Y, et al. Neuropsychological outcome of children with intrauterine growth restriction: a 9-year prospective study. Pediatrics 2006; 118:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/92\">",
"      Leitner Y, Fattal-Valevski A, Geva R, et al. Neurodevelopmental outcome of children with intrauterine growth retardation: a longitudinal, 10-year prospective study. J Child Neurol 2007; 22:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/93\">",
"      Leonard H, Nassar N, Bourke J, et al. Relation between intrauterine growth and subsequent intellectual disability in a ten-year population cohort of children in Western Australia. Am J Epidemiol 2008; 167:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/94\">",
"      Puga B, Ferr&aacute;ndez Long&aacute;s A, Garc&iacute;a Romero R, et al. Psychomotor and intellectual development of children born with intrauterine growth retardation (IUGR). J Pediatr Endocrinol Metab 2004; 17 Suppl 3:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/95\">",
"      Wienerroither H, Steiner H, Tomaselli J, et al. Intrauterine blood flow and long-term intellectual, neurologic, and social development. Obstet Gynecol 2001; 97:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/96\">",
"      Vossbeck S, de Camargo OK, Grab D, et al. Neonatal and neurodevelopmental outcome in infants born before 30 weeks of gestation with absent or reversed end-diastolic flow velocities in the umbilical artery. Eur J Pediatr 2001; 160:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/97\">",
"      Baschat AA. Neurodevelopment following fetal growth restriction and its relationship with antepartum parameters of placental dysfunction. Ultrasound Obstet Gynecol 2011; 37:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/98\">",
"      Arcangeli T, Thilaganathan B, Hooper R, et al. Neurodevelopmental delay in small babies at term: a systematic review. Ultrasound Obstet Gynecol 2012; 40:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/99\">",
"      Figueras F, Cruz-Martinez R, Sanz-Cortes M, et al. Neurobehavioral outcomes in preterm, growth-restricted infants with and without prenatal advanced signs of brain-sparing. Ultrasound Obstet Gynecol 2011; 38:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/100\">",
"      Eixarch E, Meler E, Iraola A, et al. Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution. Ultrasound Obstet Gynecol 2008; 32:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/101\">",
"      Edmonds CJ, Isaacs EB, Cole TJ, et al. The effect of intrauterine growth on verbal IQ scores in childhood: a study of monozygotic twins. Pediatrics 2010; 126:e1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/102\">",
"      Kanaka-Gantenbein C, Mastorakos G, Chrousos GP. Endocrine-related causes and consequences of intrauterine growth retardation. Ann N Y Acad Sci 2003; 997:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/103\">",
"      Kaijser M, Bonamy AK, Akre O, et al. Perinatal risk factors for ischemic heart disease: disentangling the roles of birth weight and preterm birth. Circulation 2008; 117:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/104\">",
"      Huxley RR, Shiell AW, Law CM. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure: a systematic review of the literature. J Hypertens 2000; 18:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/105\">",
"      Hallan S, Euser AM, Irgens LM, et al. Effect of intrauterine growth restriction on kidney function at young adult age: the Nord Tr&oslash;ndelag Health (HUNT 2) Study. Am J Kidney Dis 2008; 51:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/106\">",
"      Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA 2008; 300:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/107\">",
"      Crispi F, Bijnens B, Figueras F, et al. Fetal growth restriction results in remodeled and less efficient hearts in children. Circulation 2010; 121:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/108\">",
"      Bakketeig LS, Hoffman HJ. The tendency to repeat gestational age and birth weight in successive births, related to perinatal survival. Acta Obstet Gynecol Scand 1983; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/109\">",
"      Patterson RM, Gibbs CE, Wood RC. Birth weight percentile and perinatal outcome: recurrence of intrauterine growth retardation. Obstet Gynecol 1986; 68:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/110\">",
"      Surkan PJ, Stephansson O, Dickman PW, Cnattingius S. Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med 2004; 350:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/111\">",
"      Salihu HM, Sharma PP, Aliyu MH, et al. Is small for gestational age a marker of future fetal survival in utero? Obstet Gynecol 2006; 107:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/112\">",
"      Gordon A, Raynes-Greenow C, McGeechan K, et al. Stillbirth risk in a second pregnancy. Obstet Gynecol 2012; 119:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/113\">",
"      Smith GC, Wood AM, Pell JP, Dobbie R. Sudden infant death syndrome and complications in other pregnancies. Lancet 2005; 366:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/114\">",
"      Uzan S, Beaufils M, Breart G, et al. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991; 337:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/115\">",
"      Leitich H, Egarter C, Husslein P, et al. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. Br J Obstet Gynaecol 1997; 104:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/116\">",
"      CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/117\">",
"      Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; :CD004659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/118\">",
"      Horvath A, Koletzko B, Szajewska H. Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials. Br J Nutr 2007; 98:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/27/23994/abstract/119\">",
"      G&uuml;lmezoglu AM, Hofmeyr GJ. Betamimetics for suspected impaired fetal growth. Cochrane Database Syst Rev 2001; :CD000036.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6768 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23994=[""].join("\n");
var outline_f23_27_23994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1730312\">",
"      Antepartum fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Serial fetal weight assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Doppler velocimetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6217313\">",
"      Umbilical artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6217358\">",
"      Middle cerebral artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6217320\">",
"      Ductus venosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6220639\">",
"      - Biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13307467\">",
"      - Outpatient versus inpatient monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6217351\">",
"      Temporal sequence of fetal deterioration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1730474\">",
"      Frequency of fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antenatal steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medical interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TIMING OF DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6217432\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Remote from term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Late preterm and term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTRAPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RECURRENCE RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MANAGEMENT OF SUBSEQUENT PREGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antepartum management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6768|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31022\" title=\"figure 1\">",
"      Sequential changes during fetal hypoxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/6/13422\" title=\"figure 2\">",
"      SGA morbidity mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/54/33643\" title=\"table 1\">",
"      Genetic causes of FGR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/54/17261\" title=\"table 2\">",
"      Birth weight percentiles by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/61/9180\" title=\"table 3\">",
"      IUGR management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/19/18747\" title=\"table 4\">",
"      SGA stillbirth association",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/63/13302?source=related_link\">",
"      Interpregnancy interval and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14233?source=related_link\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10616?source=related_link\">",
"      Overview of causes of and risk factors for fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39477?source=related_link\">",
"      Possible role of low birth weight in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/25?source=related_link\">",
"      Prenatal sonographic assessment of fetal weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=related_link\">",
"      Umbilical cord blood acid-base analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_27_23995="DSM undiff somatoform";
var content_f23_27_23995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F73919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F73919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for undifferentiated somatoform disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A. One or more physical complaints, eg, fatigue, anorexia, gastrointestinal or urinary complaints.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Either 1 or 2:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. After appropriate investigation, the symptoms cannot be fully explained by a known nonpsychiatric medical condition or the direct effects of a substance (eg, a drug of abuse or a medication).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. When there is a nonpsychiatric medical condition, the physical complaints or resulting social or occupational impairment is in excess of what would be expected from the history, physical examination, or laboratory findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. The duration of the disturbance is at least six months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. The disturbance is not better accounted for by another mental disorder (eg, another somatoform disorder, sexual dysfunction, mood disorder, anxiety disorder, sleep disorder, or psychotic disorder).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F. The symptoms are not intentionally produced or feigned, as in factitious disorder or malingering.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright &copy; 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23995=[""].join("\n");
var outline_f23_27_23995=null;
var title_f23_27_23996="Prognosis occult breast CA";
var content_f23_27_23996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Studies addressing prognosis of occult breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Place",
"       </td>",
"       <td class=\"subtitle1\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        5 year OS, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ashikari, R; 1976",
"       </td>",
"       <td>",
"        Memorial Hospital, NYC",
"       </td>",
"       <td>",
"        1946-75",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campana, F; 1989",
"       </td>",
"       <td>",
"        Institute Curie",
"       </td>",
"       <td>",
"        1960-85",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baron, P; 1990",
"       </td>",
"       <td>",
"        MSKCC",
"       </td>",
"       <td>",
"        1975-88",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ellerbroek, N; 1990",
"       </td>",
"       <td>",
"        MD Anderson",
"       </td>",
"       <td>",
"        1944-87",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rosen, P; 1990",
"       </td>",
"       <td>",
"        MSKCC",
"       </td>",
"       <td>",
"        1966-85",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kyokane, T; 1995",
"       </td>",
"       <td>",
"        Japan",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Foroudi, F; 2000",
"       </td>",
"       <td rowspan=\"2\">",
"        Australia",
"       </td>",
"       <td rowspan=\"2\">",
"        1979-96",
"       </td>",
"       <td rowspan=\"2\">",
"        20",
"       </td>",
"       <td>",
"        93 (mastectomy or XRT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41 (no local treatment)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Matsuoka, K; 2003",
"       </td>",
"       <td>",
"        Japan",
"       </td>",
"       <td>",
"        1985-98",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Blanchard, D; 2004",
"       </td>",
"       <td rowspan=\"2\">",
"        Mayo",
"       </td>",
"       <td rowspan=\"2\">",
"        1975-98",
"       </td>",
"       <td rowspan=\"2\">",
"        35",
"       </td>",
"       <td>",
"        73 (mastectomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36 (no mastectomy)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: Not reported; OS: Overall survival; MSKCC: Memorial Sloan Kettering Cancer Center; NYC: New York City.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23996=[""].join("\n");
var outline_f23_27_23996=null;
var title_f23_27_23997="Selected translocations in sarcomas";
var content_f23_27_23997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected translocations associated with sarcomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Translocation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Genes",
"      </td>",
"      <td class=\"subtitle1\">",
"       Type of fusion gene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Ewing's sarcoma (OMIM#133450)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(11;22)(q24;q12)",
"      </td>",
"      <td>",
"       EWSR1-FLI1",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(21;22)(q22;q12)",
"      </td>",
"      <td>",
"       EWSR1-ERG",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(7;22)(p22;q12)",
"      </td>",
"      <td>",
"       EWSR1-ETV1",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(17;22)(q12;q12)",
"      </td>",
"      <td>",
"       EWSR1-ETV4",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(2;22)(q35;q12)",
"      </td>",
"      <td>",
"       EWSR1-FEV",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(2;16)(q35;p11)",
"      </td>",
"      <td>",
"       FUS-FEV",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(16;21)(p11;q24)",
"      </td>",
"      <td>",
"       FUS-ERG",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Clear-cell sarcoma (OMIM#123803)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(12;22)(q13;q12)",
"      </td>",
"      <td>",
"       EWSR1-ATF1",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Desmoplastic small round-cell tumor of the abdomen (OMIM#133450)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(11;22)(p13;q12)",
"      </td>",
"      <td>",
"       EWSR1-WT1",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Myxoid chondrosarcoma (OMIM#600542)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(9;22)(q22-31;q11-12)",
"      </td>",
"      <td>",
"       EWSR1-NR4A3",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Myxoid liposarcoma (OMIM#126337, #137070)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(12;16)(q13;p11)",
"      </td>",
"      <td>",
"       FUS-DDIT3",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(12;22)(q13;q12)",
"      </td>",
"      <td>",
"       EWSR1-DDIT3",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Alveolar rhabdomyosarcoma (OMIM#268220)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(2;13)(q35;q14)",
"      </td>",
"      <td>",
"       PAX3-FOXO1A*",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(1;13)(p36;q14)",
"      </td>",
"      <td>",
"       PAX7-FOXO1A*",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Synovial sarcoma (OMIM#312820)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(X;18)(p11;q11)",
"      </td>",
"      <td>",
"       SYT-SSX",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Dermatofibrosarcoma protuberans (OMIM#607907)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(17;22)(q22;q13)",
"      </td>",
"      <td colspan=\"1\">",
"       COL1A1-PDGFB",
"      </td>",
"      <td>",
"       Growth factor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Congenital fibrosarcoma (OMIM#191316)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(12;15)(p13;q25)",
"      </td>",
"      <td>",
"       ETV6-NTRK3",
"      </td>",
"      <td>",
"       Transcription factor receptor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Inflammatory myofibroblastic tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"       2p23 rearrangements",
"      </td>",
"      <td>",
"       TMP3-ALK;",
"      </td>",
"      <td>",
"       Growth factor receptor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TMP4-ALK",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"       Alveolar soft-part sarcoma (OMIM#606243)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       t(X;17)(p11.2;q25)",
"      </td>",
"      <td>",
"       ASPL-TFE3",
"      </td>",
"      <td>",
"       Transcription factor",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that for some tumors, notably Ewing's sarcoma, multiple variant translocations have been observed involving related genes.",
"    <div class=\"footnotes\">",
"     OMIM: Online Mendelian Inheritance in Man, available at file://www.ncbi.nlm.nih.gov/sites/entrez?db=omim.",
"     <br>",
"      * FOXO1 A gene also known as the FKHR gene.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nature Reviews: Cancer 2003; 3:685. Copyright &copy; 2003 MacMillan Magazines Ltd.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23997=[""].join("\n");
var outline_f23_27_23997=null;
var title_f23_27_23998="Atrial tachycardia algorithm";
var content_f23_27_23998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    P-wave algorithm to predict anatomic origin of atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A P-wave algorithm constructed on the basis of findings from 130 atrial tachycardias correctly localized the focus in 93 percent. The algorithm begins with assessment of the P-wave morphology in lead V1 on the surface electrocardiogram, then utilizes other leads as needed.",
"    <div class=\"footnotes\">",
"     Neg: negative P-wave morphology; Pos: positive P-wave morphology; Iso: isoelectric P-wave morphology; CS: coronary sinus ostium; CT: crista terminalis; LAA: left atrial appendage; LPV: left inferior pulmonary vein; LS: left superior pulmonary vein; RAA: right atrial appendage; RPV: right inferior pulmonary vein; SMA: superior mitral annulus; TA: tricuspid annulus.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kistler, PM, Roberts-Thomson, KC, Haqqani, HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol 2006; 48:1010. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23998=[""].join("\n");
var outline_f23_27_23998=null;
var title_f23_27_23999="Mastoiditis";
var content_f23_27_23999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mastoiditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: B. Welleschik. Available at: file://commons.wikimedia.org/wiki/File:Mastoiditis1.myextj.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_27_23999=[""].join("\n");
var outline_f23_27_23999=null;
